“Multifunctional Role of Neurodegenerative Disorder: A Systemic Review”

Submitted To

Dr. Mohammed Shafikur Rahman

Assistant Professor

Department of Pharmacy

Faculty of Allied Health Science

Daffodil International University

Submitted By

Pranta Das

Student ID: 213-46-387

Batch:13th

Department of Pharmacy

Faculty of Allied Health Science

Daffodil International University

Submission Date: 23 December, 2022

APPROVAL

This Thesis, **"Multifunctional Role of Neurodegenerative Disorder: A Systemic Review",** submitted by Dr. Mohammed Shafikur Rahman, Associate Professor, Department of Pharmacy, Daffodil International University, has been accepted as satisfactory for the partial fulfillment of the requirements for the degree of Master of Pharmacy and approved as to its style and contents.

Supervised By



Dr. Mohammed Shafikur Rahman
Associate Professor
Department of Pharmacy

Daffodil International University

Pranta Das
Author



BOARD OF EXAMINERS

---------- **Head**

Professor Dr. Muniruddin Ahamed

Professor and Head

Department of Pharmacy

Faculty of Allied Health Science

Daffodil International University

---------- **Internal Examiner-1**

---------- **Internal Examiner-2**

---------- **External Examiner**

Abstract

Amyloid-beta (A) AD aggregation, neuroinflammation, and a number of other processes are altered in cells as a result of Alzheimer's disease (AD), a prevalent neurodegenerative brain condition. The most common type of dementia, AD, continues to impact a large number of people worldwide. It's unclear what exactly caused the disease. As of right now, there are no effective drugs to slow down, stop, or cure AD. Numerous natural substances are extracted from various sources and studied in preclinical and clinical settings for their neuroprotective effects in the prevention and treatment of AD. Additionally, the treatment and prevention of AD have shown promise for natural compounds and their derivatives. Natural bioactive substances actively modulate the pathogenic molecular processes that lead to the development of AD.This review focuses on plant-based natural compounds and their derivatives that have shown neuroprotective properties and may show promise in the treatment and prevention of AD. The literature on using natural items as AD therapy agents is also summarized in this article. Most bioactive compounds have limitations in treating AD, including rapid metabolism, nonspecific targeting, low solubility, lack of BBB permeability, and limited bioavailability. We can employ nanotechnology and Nano carriers based on several strategies.

Keywords: Alzheimer's disease, natural products, amyloid –beta, neurofibrillary tangles, reactive oxygen species

Contents

CHAPTER ONE

INTRODUCTION

1. Introduction

Alzheimer`s disease (AD) is a neurological circumstance that worsens with age and impairs reminiscence and cognitive function. It is the 5th best motive of demise and money owed for 60–80% of all times of dementia [4]. Alzheimer's disease (AD) is a neurodegenerative illness (NDD) that step by step and completely impairs reminiscence, cognition, and in the end the potential for ordinary duties, making full-time employment vital care. Although it is able to harm more youthful humans as well, the circumstance is extra not unusualplace in humans over 65. Age is one of the maximum vital hazard elements for AD. According to studies, the superiority of Alzheimer`s dementia rises sharply with age, with 3% of these elderly sixty five to 74, 17% of these elderly seventy five to 84, and 32% of these elderly eighty five or older having the disease. The pathophysiology of Both environmental and genetic variables have an effect on AD[7]. This is due to the fact extracellular amyloid and lipid deposits NFTs (intracellular neurofibrillary tangles) are of the maximum extraordinary pathologic traits of AD [8]. Clinical dementia is added on with the aid of using amyloid buildup, which additionally reasons cognitive deterioration [9]. Amyloid- beta (A) peptide synthesis and neuronal dying are each suffering from mutations withinside the amyloid precursor protein (APP) and presenilin, which might be each worried withinside the improvement of AD [10, 11]. Unexpectedly, clean studies discovered that neuro irritation is a critical pathogenic aspect of Alzheimer's disease [12]. In assessment to intracellular neurofibrillary tangles (NFTs), which can be as a result of tau protein hyper phosphorylation in neurons, extracellular protein a aggregates for the duration of the improvement of AD. These neurons, which reason neuronal mobileular death, are typically gift withinside the cerebral cortex and hippocampus of the brain [13]. Inflammation and oxidative strain are introduced on with the aid of using the deposition of aggregated A protein withinside the synapses of Alzheimer`s patients (OS). Depletion of cholinergic neurotransmission and immoderate glutamatergic neurotransmission are in addition functions of AD [14]. The incapacity to remember recollections is the maximum widely wide-spread and early signal of AD dementia [15]. Short-time period reminiscence impairment is usually the preliminary medical manifestation, however instant reminiscence impairment is generally gift as well. Later, remote reminiscence is likewise affected. Memory, on the alternative hand, processing that doesn't require the systems of the hippocampus lobe is not able to characteristic in AD [16, 17]. Severe dementia in its overdue degrees AD generally consequences in folks dropping their cappotential to stroll and speaking really consequences in

intense reminiscence loss further to dropping their experience of location and time. In this example Patients want greater attention. In the following 50 years, it's far believed that healing motion can put off the start or improvement of AD might be Significantly decreased there were 18 cases. The improvement of medication for the remedy of AD has correctly and promisingly used herbal merchandise and their bioactive compounds as potential healing leads [19, 20]. This is due to the fact combos or extracts of herbal items encompass natural bioactive compounds that can be used as a healing technique to deal with or save you AD [21–23]. Additionally, loads of extracts and herbal reassets are extensively utilized in scientific trials and animal fashions of AD [24, 25]. This assessment emphasizes the healing cappotential of plant-primarily based totally herbal merchandise which can have neuroprotective residences for the manipulate and remedy of AD thru loads of mechanisms, primarily based totally at the preceding dialogue and because of the huge variety of preventive and healing alternatives to be had for herbal merchandise of plant origin.

CHAPTER TWO
THE OBJECTIVE OF MY STUDYES

2. The objective of my studies given below:

- Concentrated on the pathogenesis & characteristic of Alzheimer's disease (AD).

- How using natural products could be crucial for managing and treating AD.

- The interaction between natural products and endoplasmic reticulum stress in the prevention of neuroinflammation and oxidation.

- Nanotechnology derived from natural sources could be a promising alternative for the treatment of AD.

CHAPTER THREE

METHOLOGY

3. Methodology

After doing a literature search, we were able to find current, pertinent references in a variety of databases, including Scopus, Science Direct, Elsevier, PubMed, and Web of Science. The terms "medicinal plant," "neuroprotection," "Alzheimer's illness," "antioxidant," and "inflammation" were used in our search. Research reports, reviews, and original research papers published in English up until October 2021 were chosen and assessed.

4. Pathology of AD

The pathological symptoms and symptoms and signs of AD are amyloid plaques and NFTs. In addition, AD additionally reveals cerebral amyloid antipathy, neuropil threads, dystrophic neurites, related astrogliosis, and microglial activation [28]. These pathologic procedures reason neurodegeneration, such as synaptic and neuronal loss, which leads to macroscopic atrophy. The neurodegenerative dementia called combined pathology, which incorporates vascular sickness and Lewy bodies, is every other not unusualplace type in older adults [29]. In fact, familial AD and Lewy frame sickness regularly overlap, at the same time as the precise mechanism is uncertain [30]. Additionally, TDP- forty three pathology is an increasing number of diagnosed as a pathology [31]. Amyloid plaques, by-merchandise of APP metabolism, are extracellular clumps in most cases composed of misfolded A proteins with forty or forty two amino acids (A40 and A42). A-forty two is greater commonplace in plaques than A-forty because of its better price of insolubility and fibrillation. Although the formation of amyloid deposition won't usually observe a predictable pattern, it usually begins offevolved withinside the cortex and handiest impacts subcortical areas later. Amyloid plaques, in comparison to NFTs, have a negligible impact at the entorhinal cortex and hippocampal formations. On the alternative hand, the bulk of NFTs are composed of hyper phosphorylated tau paired helical filaments (PHFs). The fundamental sensory, motor, and visible domain names are in large part freed from tau illness, which frequently starts offevolved withinside the medial temporal lobes (entorhinal cortex and hippocampus) after which progresses to the associative is cortex. The pathogenesis of NFT is higher connected to the medical developments and severity of AD due to the fact neuronal and synaptic loss often happens on the identical time as tangle growth [32]. On the alternative hand, early withinside the disease`s medical phase, A pathology reaches a plateau [33].

5. Etiology and Pathophysiology of AD

Despite the reality that Aloise Alzheimer, a German physician, first recognized AD extra than a century ago, the primary mechanisms at the back of its improvement are nevertheless unknown [34]. Anomic aphasia,

acalculia, and apathy are not unusualplace signs of AD, as are dementia, reminiscence loss, mobility issues, depression, delusion, impairment of spatial awareness, and hallucinations. Additionally, people who are in the direction of the give up of the disease`s path are not able to talk verbally, have misplaced their independence, and are not able to carry out easy every day duties [35, 36]. These aberrant behavioral behaviors related to AD are symptoms and symptoms of underlying CNS techniques. The etiopathogenesis of this contamination remains now no longer absolutely known, in spite of non-stop research. However, on the mobile and tissue levels, sure one of a kind pathways had been discovered. In this situation, the buildup of A is an ordinary signal of AD. Senile plaque APP is created with the aid of using synthesizing a brief peptide referred to as A from certainly taking place APP. Additionally, A controls synaptic plasticity, participates in axonal increase, and modifies axonal increase in physiological conditions. [36, 37]. Development is often followed with the aid of using in addition pathogenic abnormalities that harm the shape of pyramidal neurons. These techniques result in the introduction of tau tangles and are precipitated with the aid of using multiplied phosphorylation of tau proteins (Figure 2).Tau proteins even have a position withinside the physiological stabilization of microtubules and, consequently, the cytoskeleton shape. In this regard, microtubules function mobile proteins and enzyme transporters, making sure accurate neuron hobby and synaptic signaling. Tau proteins and tubulins connect with shape the sensitive systems referred to as microtubules, that are depending on those interactions for stability. Inducing microtubule breakdown and growing the improvement of tau tangles, that are indicative of AD, multiplied tau phosphorylation causes. Similarly, cyclin-established kinase five has been related to this technique due to the increased Ca2+ ion attention this is at once delivered on with the aid of using the aggregation of a internal nerve cells.

Thus, the cytoskeleton deforms, intracellular shipping is disturbed, microtubules depolymerize, and the neuron`s common characteristic is diminished. Microglia are activated with the aid of using poisonous aggregates determined in tau tangles, which bring about mobileular death, neuronal damage, and inflammation. While numerous theories were positioned out to provide an explanation for the pathophysiology of AD, the best mechanism continues to be doubtful and complex [39]. Some of the hypotheses which have been positioned out consist of the following:

(4.1) Cholinergic Hypothesis. Cholinergic neurotransmission impacts intellectual state, mind adaptation, sleep-wake cycle management, cerebral blood go with the drift control, and neuronal characteristic. Studies display that the cholinergic gadget is likewise essential for cognitive characteristic. As a result, reminiscence loss will be delivered on with the aid of using impairment [40, 41]. Acetylcholine (ACh) is launched at synapses at some stage in cholinergic neurotransmission. ACh is hydrolyzed with the aid of using acetylcholinesterase (AChE) and butyrylcholinesterase, which terminates the signal (BuChE). In this situation, numerous AD sufferers displayed unchanged or accelerated BuChE activity. Ache and BuChE inhibition is a promising approach for treating AD on account that it's miles cautioned that Ache-prompted A aggregation contributes to the improvement of AD and the manufacturing of neurotoxic A fibrils [42].

(4.2) Hypothesis of Amyloid. A precursor protein (APP) is a kind I transmembrane sialo glycoprotein this is encoded with the aid of using a unmarried gene on chromosome 21's 19 exons. APP is available in 3 one of a

kind forms: APP751, APP770, and APP695. The APP regulates synaptic plasticity, mobileular adhesion, intracellular calcium degree stabilization, neurite outgrowth, and mobileular adhesion. The crucial occasion is the -secretase enzyme cleaving Lys16 of the APP, liberating an A-soluble peptide and C-terminal fragment. On the alternative hand, the C- terminal place is break up with the aid of using -secretase to create the nonamyloidogenic peptidep3.



Figure 1: The Alzheimer's disease amyloid cascade (AD). Amyloid-beta, neurofibrillary tangle, amyloid precursor protein, reactive oxygen species, nitric oxide, and tumor necrosis factor-alpha are all abbreviations for the endoplasmic reticulum (ER) [38].

In contrast, APP is damaged down through -secretase into soluble A peptides and a C-terminal fragment. Additionally,-secretase breaks down APP in numerous places, generating an A monomer with amino acids among 38 and 43. After that, a monomers self-collect into neurotoxic oligomers, which in flip set off fibrillary aggregates to form, which in the long run bring about neuronal disorder and dementia [44]. Additionally, the formation of senile plaques, a function of AD, is induced through aggregated oligomers. The A-forty two peptide is found in Alzheimer`s sufferers at fantastically more tiers than usual. Additionally, APOE, PSEN1, and PSEN2 have an effect on a etiology, consistent with genetic studies [45].

4.3 Hypothesis of Tau. An instance of a phosphoprotein is tau. There are six isoforms with lengths starting from 352 to 441 amino acids and 38 phosphorylation sites. In this way, the microtubule interactions and amino acid make-up of the tau domain names are used to outline them. The amino-terminal element on this example is called a "projection area" because it does now no longer connect to microtubules however rather extends beyond them. Additionally, the projection area is split into an amino-terminal and proline-wealthy, acidic residue-wealthy sections. The tubulin-binding phase and the acidic carboxy-terminal part of the microtubule-binding area also are divided [39]. By interacting with tubulin, phosphorylated tau protein contributes to intracellular trafficking and stabilizes axonal microtubule assembly [46]. Normal tau is transferred to NFTs and matched helical filament tau because of aberrant tau phosphorylation (PHF-tau). Microtubules are made volatile with the aid of using hyper phosphorylated tau, which kills nerve cells. According to research, hyper phosphorylated tau

is 3 to 4 instances greater ordinary withinside the brains of AD sufferers than it's miles in healthful individuals [47].

4.4 Neuro inflammation. By liberating proinflammatory cytokines which include interferon, interleukin 1, and tumor necrosis factor (TNF), that have been detected in AD sufferers and feature an effect at the brain, expanded ranges of microglia and astrocytes produce continual neuro inflammation. This is because -secretase, which cleaves APP to supply an A peptide, works higher while reactive oxygen species (ROS) are present [46]. As a result, novel chemical substances that may be applied to deal with and save you AD were created the usage of anti- inflammatory approaches [48].

4.5 Biometal Dyshomeostasis. Biochemical tactics like protein structural stability, metabolism, catalytic activity, and cell sign transmission all rely on metals like copper, iron, and zinc [49]. The Fenton reaction, that's generally pushed through redox energetic Fe2+ and Cu2+, can generate extra unfastened radicals, that could growth the manufacturing of DNA, proteins, and lipids. Therefore, dysregulation of bio metals in neurodegenerative sicknesses like AD reasons an growth in oxidative stress, that's why metallic chelators might also additionally have a function in inhibiting AD progression [50, 51].

4.6 Oxidative Stress (OS). ROS consisting of the hydroxyl radical, superoxide anion radical, peroxide, and hydrogen peroxide are produced via way of means of oxygen intake and mobile signaling. In usual circumstances, the intrinsic antioxidant device controls the stability of ROS [52]. However, in pathological conditions, there may be a disparity among ROS era and clearance, ensuing in multiplied ROS levels [53]. Brain OS can be a precursor of AD and can affect the direction of the disease, in keeping with research [54, 55]. The chance of ROS publicity is better withinside the mind as it makes use of the maximum energy, consumes the maximum oxygen in comparison to different organs, and plays mitochondrial respiration. On the opposite hand, A formation and deposition in AD are stimulated via way of means of lipid peroxidation and protein oxidation [56, 57].

4.7 Insulin-Degrading Enzyme. Type 2 diabetes and insulin resistance withinside the mind are related to AD. Studies hyperlink tau hyper phosphorylation and A deposition to the insulin-degrading enzyme (IDE). IDE is visible via way of means of insulin and A as a rival substrate that contributes to the pathogenesis of AD. Additionally, IDE is hooked up to the clearance of A withinside the mind. IDE activators can consequently be applied to deal with AD.

4.8 Homocysteine. Homocysteine (HCy), a nonproteinogenic homolog of cysteine, is produced after methionine is demethylated. Inducing glutamate excitotoxicity, which leads to neurotoxicity and in the long run results in neuronal death, is what occurs whilst HCy attaches to glutamate NMDA receptors. High degrees of HCy are related to oxidative damage, apoptosis, A aggregation, and tau protein hyper phosphorylation [58, 59].

4.9 Phosphodiesterase. Cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate are damaged down through the enzymes called phosphodiesterase (PDEs) (cAMP). They additionally take part withinside the law of intracellular signaling cascades and synaptic plasticity. Particularly PDE4, PDE7, and

PDE8 expression adjustments were linked to AD [60]. Additionally, rodents just like the new global beaver, fungi like ergot, and amphibians just like the poison dart frog produce alkaloids. It`s thrilling to notice that the 2 AChEIs accredited through the Food and Drug Administration (FDA) withinside the United States, rivastigmine and galantamine, are alkaloids [64, 66].

5.1.1 Galantamine. Galanthus caucasicus, Galanthus sworonowii, and Leucojum aestivum are all Amaryllidaceous flora that produce the isoquinoline alkaloid galantamine of their plants and bulbs [67]. Nicotinic acetylcholine receptors (nAChRs) are modulated allosterically via way of means of galantamine [68, 69]. By affixing linkers of various lengths and substances to meantime, many glutamine derivatives have been created. These materials have been evaluated for his or her capacity to inhibit AChE and their selectivity for NMDAR binders and NMDAR subunit 2B. (NR2B). Some artificial compounds tested outstanding inhibition of AChE with IC50 values of nanomolar and micro molar affinity for NMDAR. Some derivatives tested a micro molar affinity for the NMDAR with the 2B subunit (NR2B) whilst examined for selectivity. Finally, a cell-primarily based totally assay become used to assess the neuroprotective hobby of a subset of drugs. The IC50 cost of one of the synthesized compounds become 0.28 nM, even as 3 of the acquired compounds had notable neuroprotective effects, lowering NMDA-brought about neurotoxicity at subnanomolar concentrations [70]. In addition, rhAChE become docked with a brand-new hybrid twin-web website online binding compound made from galantamine and indole. Three of the synthesized compounds confirmed AChE inhibitory hobby with I C50 values of 0.011 M, 0.012 M, and 0.half M. Galantamine-indole compounds that characteristic as twin web website online binders to the rhAChE enzyme are produced due to interactions among the galantamine moiety and the CAS and the indole aspect and the fragrant residues withinside the peripheral anionic web website online [71].

6. Natural Products

Scientists commenced searching into the characteristic of plant bioactive compounds whilst studies consequences confirmed that unique nutritional additives decreased the prevalence of AD [61]. "Secondary metabolites" of flora are taken into consideration to be evidently taking place bioactive compounds. In this regard, a lot of compounds remoted from diverse plant parts, including roots, rhizomes, leaves, and seeds, were proven to restriction the boom of negative plaque and to sell cholinergic signaling [62, 63].(Figure 3). Foods excessive in antioxidants lessen mind oxidative stress. Since of this, scientists are interested by the use of plant-derived chemical substances to create compounds that may deal with a lot of illnesses due to the fact they have got a extensive variety of pharmacological effects [64, 65]. Results indicated that a few evidently taking place bioactive materials are enough for coping with AD. Below are specifics on those materials (Figure 4).

5.1 *Alkaloids.* Alkaloids are a collection of nitrogenous chemical substances which might be extensively disbursed in recognized households of flowering plants. While a few species handiest produce some alkaloids, others, like the ones withinside the Ranunculaceae, Solanaceae, Papaveraceae, and Amaryllidaceae households, have many alkaloids [62, 66].

5.1.2 Huperzines. Two lycopodium alkaloids referred to as hopper zines A and B are recognized from the Chinese medicinal plant hopperzia serrata (membership moss), that's used to therapy situations like edema, disorientation, schizophrenia, fever, and strain. With IC50 values of 0.eighty two and 74.forty

three nM, respectively, huperzine A inhibits AChE and BuChE in a particular, efficient, and reversible manner [72, 73]. The reversible drug huperzine B is similar. AChE inhibitor having an IC50 fee of 14.three M [74]. As a result, huperzines A and B are extensively used as herbal moieties to create AChEIs which might be extra potent.

Additionally, novel AChE inhibitors primarily based totally at the carbobicyclo and 4-aminoquinoline substructures of huperzine A with AChE substitutes had been proposed in lots of forms. impeders [75]. In addition, different heterodimers with donepezil dimethoxyindanone and huperzine A pyridone related through a distinct methylene linker had been concept to be AChE inhibitors with ability usefulness in treating AD [76]. It`s thrilling to notice that novel huperzine A and imine derivatives with a further small substituted fragrant ring show off effectiveness as hACh withinside the nanomolar range. As hACh. inhibitors, novel huperzine A and imine derivatives with a further small substituted fragrant ring show off effectiveness withinside the nanomolar range [77], in which the fragrant earrings of the huperzine derivatives display a - stacking with AChE amino acid residues.



Figure 3: A diagram of the mechanisms by which natural remedies prevent Alzheimer's disease (AD).

In addition, smart use of recent huperzine B compounds developed. A tether chain connects the huperzine B moiety to the terminal fragrant ring, facilitating interplay with the PAS, or peripheral anionic web website online. Rhein`s hydroxyanthraquinone device has been connected to a thing of heparin Y to provide precise multitarget rhein-huprin hybrids using a number of linkers. Involvement of Huprin Y with an energetic while the

fragrant earrings in their make stacking interactions with the PAS of AChE, growing a dualsite inhibitor, on the catalytic web website online (CAS).

5.1.3. Berberine. A benzylisoquinoline alkaloid recognized as "berberine" has been determined in Berberis species and Phellodendron amurense's rhizomes, stems, roots, and bark. Strong anti-inflammatory, anticancer, antibacterial, aerobic protective, and neuroprotective homes are present [80–82]. Additionally, berberine inhibits each BuChE and AChE, whilst AChE is extra particularly targeted. Additionally, berberine suppresses the voltage-based potassium cutting-edge and has an adversarial effect at the NMDA receptor, mainly NR1, which allows to shield the worried device. So, via way of means of growing cholinergic activation, berberine reduces cognitive impairment in AD [83, 84]. Additionally, novel triazole and berberine dual-web website online binding compounds have been docked with Torpedo California acetylcholinesterase (TcAChE) [85]. By substituting a sulfur atom for an oxygen or NH organization withinside the berberine derivatives, the antioxidant abilities of the ensuing berberine-thiophenyl hybrids have been accelerated. Additionally, those hybrids had antioxidant homes and decreased A aggregation [86].

5.1.4. Aporphine. Menispermum dauricum yields aporphine alkaloids, which belong to the isoquinoline elegance of alkaloids and feature a tetrahydroisoquinoline substructure [87, 88]. Oxoisoaporphine and oxoaporphine are examples of opioid alkaloids which have a lot of organic effects, such as the capacity to inhibit telomerase, cholinesterase, and A aggregation in addition to antioxidant action [87, 89]. In this respect, artificial oxoaporphine derivatives are to a few instances much less powerful as AChE inhibitors than their oxoisoaporphine analogs. According to molecular modeling studies, the Trp279 residue of the PAS of AChE should bind to the azabenzanthrone moiety of the oxoisoaporphine alkaloids through a stacking contact. . The oxoisoaporphine alkaloid's selectivity in the direction of AChE and water solubility have been drastically accelerated via way of means of the usage of amines or ammonium companies as spacers [87]. A brand-new series of oxoisoaporphine-tacrine hybrids changed into joined via way of means of an amino alkyl tether. These new materials had antiaggregating homes; at concentrations of 10 M, they have been robust inhibitors of self-brought about A aggregation (35.5-85.8%) [89]. Eight nuciferine derivatives have been additionally produced via way of means of the techniques of dealkylation and ring aromatization. Products containing 1,2-dihydroxyaporphine and dehydronuciferine have been determined to consist of AChE inhibitors with IC50 values of 28 and 25 g/mL [90]

5.1.5 Flavonoids and Other Polyphenols. Polyphenols known as flavonoids are found in culmination and vegetables. These are good sized withinside the plant companies Polygonaceae, Rutaceae, and Leguminosae [47, 64]. Because in their polyphenolic makeup, flavonoids have neuroprotective homes due to the fact they scavenge loose radicals like superoxide and hydrogen peroxide. In polyphenols, the variety and place of hydroxyl companies have an effect on how properly they could scavenge loose radicals. A novel line of flavonoid derivatives changed into created due to their antioxidant homes [65, 66]. Different subgroups of flavonoids are shaped relying on the location of the B ring, the extent of.

Flavanone



Galantamine



Huperzine A

Huperzine B



Berberine



Aporphine



Isoflavones



Catechin



Flavanone



Flavonol



Flavone



Chalcone



Coumarin



Curcumin



Figure 4. shows the chemical composition of certain substances that are useful at preventing Alzheimer's disease (AD)

The 3-phenylchromen4-one structure of isoflavones results from the B ring's attachment to position 3 of the C ring. In neoflavonoids, however, the B ring is connected to position 4 of the C ring, resulting in a 4-phenylcoumarine structure. The B ring is related to position 2 of the C ring in the following subgroups: flavones, flavone's, flavanones, flavan-3-ol or flavanols or catechins, and chalcones, with the exception of the C ring's structural characteristics [91]. Also frequently used are flavonoids, a group of phytochemicals with a range of therapeutic properties. Due to their major repressive function against proinflammatory mediators, flavonoids are crucial in reducing brain inflammation in Alzheimer's disease.

factors in transcription [92]. The anti-inflammatory and antioxidant transcription factors are also activated by this class of substances. Despite the fact that flavonoids have the potential to be a natural treatment in preclinical AD models, the average bioavailability of the parent flavonoid is often low. Flavonoids are incredibly polarized, which allows them to pass through the blood-brain barrier (BBB) [12].

5.1.6 Flavones, which have a range of health benefits, are present in numerous medicinal plants. Flavones and their derivatives, which also have biological characteristics like antioxidant, anti-inflammatory, and neuroprotective activities, block advanced glycation products (AGEs). These substances may also be useful for treating and preventing AD [92–100].

5.1.7 Isoflavones. Leguminous plants, including soybeans, and microorganisms can both be used to obtainis flavonoids. They serve as the building blocks for the production of phytoalexin during interactions between plants and microbes. AChE and MAO-B are inhibited by these substances [101].

5.1.8 Flavanones. Hesperidin belongs to the flavanones subclass of flavonoids, which is a significant one. Flavanones are found in abundance in citrus fruits like oranges, grapefruit, tangerines, lemons, and limes. Fruits like citrus are able to scavenge free radicals, lessen inflammation, and lower blood lipid levels thanks to certain qualities. Flavanones are presently being utilized more commonly in the creation of multitarget directed ligands (MTDL) [97, 98]

5.1.9 Chalcones Chalcones are another significant subgroup of open chain flavonoids since ring C is lacking from the fundamental flavonoid skeleton structure. Chalcones are found in variable levels in a wide variety of foods, such as ladies' fingers and tomatoes. Chalcones and their derivatives have drawn interest from researchers as potential anti-drugs for Alzheimer's because of their wide range of biological actions [97, 98, 102–105].

5.1.10 Neoflavonoids. Neoflavonoids are organic substances that are part of the polyphenolic compound family. Neoflavonoids have the 4-phenylchromen backbone with no substitution of the hydroxyl group at position 2, whereas flavonoids have the 2-phenylchromen-4-one backbone. In this regard, coumarin, a neoflavanoid present in many plants, serves a variety of therapeutic purposes. It interacts with the peripheralanionic site (PAS) of AChE and functions as a powerful inhibitor of AChE, inhibiting A aggregation, according to molecular modeling studies [97, 98]. A derivative was created by joining both scaffolds together using a piperazine-based alkyl spacer to create a brand-new tacrine-coumarin hybrid. The product had significant inhibitory activity against EeAChE (0.092 M) and moderate activity against EqBuChE (0.234 M) due to its amide linkage, in addition to having antiaggregation properties [106]. In coumarin- based MTDL derivatives, the 6 and 7 positions of coumarin are connected to alkyl spacers of varying lengths with a terminal diethylamino group, inhibiting human AChE at nanomolar concentrations. Additionally, these substances have a remarkable 60% inhibition of A42 selfaggregation, which has a neuroprotective impact and makes them potential disease modifiers [107].

5.2 Curcumin. For centuries, people have employed a natural compound called curcumin to cure a variety of diseases [108]. Curcumin functions well as a neuroprotective drug to treat a range of neurological diseases because of its anti-inflammatory and antioxidant properties. The long A's 40–42 amino acids.

5.3 Endoproteolytic breakdown of APP results in the production of peptide. The combination of A and curcumin appears to reduce oxidative stress, inflammation, and cognitive deficits in rats treated with A [109, 110]. Curcumin's capacity to prevent A aggregation and fibril formation has been demonstrated in both in vitro and in vivo studies.Along these lines, factors that lead to the formation of amyloid plaques include metal chelation, low cholesterol, lipid peroxidation, facilitated transcription, and decreased -secretase enzyme production [111, 112]. Curcumin affected extracellular amyloid accumulation through these signaling pathways. Curcumin also inhibits the formation of heat shock protein (HSP), which is an additional route, which prevents protein aggregation. In this way, HSP functions as molecular chaperones to stop protein aggregation. In experimental settings both in vivo and in vitro, curcumin boosted the production of HSP. Additionally, it prevented the development of dangerous amyloid aggregates and cytokines that promote inflammation in the brain [111]. On the other hand, the buildup of the tau protein within neurons is a significant contributor to AD. Aggregation is brought on by the -sheet in tau protein, which is inhibited by medications like curcumin. Additionally, curcumin is a pleiotropic and affordable treatment for neuronal dysfunction due to its multiple systemic activities [3]. Additionally, curcumin prevented A from building up in PC12 cells and human umbilical vein endothelial cells. In a Tg2576 animal model of AD, curcumin also demonstrated antioxidant and anti-inflammatory effects [113]. Similar to this, curcumin protected primary neuronal cell cultures from the neurotoxicity caused by quinolone acid. Results demonstrated that pretreatment with curcumin caused a significant drop in neuronal nitric oxide synthase. [3]

5.4 Terpenes Terpenoids, also known chemically as 2-methyl-1 or 3-butadiene, are a group of compounds produced biosynthetically from a combination of two or more isoprene units [108]. Parthenolide, a physiologically active sesquiterpene lactone found in Tanacetum parthenium, improves cognitive function while reducing TNF- and IL-6 levels in the cortex and rat hippocampus [114]. It has recently been demonstrated that neuroinflammation in intracerebral hemorrhage, which promotes brain injury in rats, canbe controlled by TLR4/NF-B-mediated reduction in the levels of TNF-, IL-6, and IL-17 in the ipsilateral hemispheres of the brain [12]. The various NF-B inhibitory actions of parthenolide appear to be responsible for its inhibitory effects in a variety of neuropathologies including inflammation. The neuroprotective properties of this sesquiterpene lactone need to be confirmed in clinical research on AD, nevertheless.

Similar to how artemisinin, a sesquiterpene lactone found in the Asteraceae family plant Artemisia annua, was initially used to treat malaria that was resistant to multiple drugs. Due to this molecule's and some of itssynthetic analogues' anti-inflammatory capabilities, researchers have recently discovered that they show promising neuroprotective action in AD [115]. It has been demonstrated that artemisinin and

its artificial derivatives penetrate the BBB because of their lipophilicity [116]. Both the carnosic acid and the carnosol found in Rosmarinus officinalis are naturally occurring diterpenes that have significant neuroprotective action [117]. No evidence from clinical trials suggests that ginkgolides are helpful in the treatment of AD. Ginkgo biloba extracts have been used in clinical trials with varying degrees of success. According to the findings of a randomized controlled study (RCT), they improved cognitive function, neuropsychiatric symptoms, and functional capacities in patients with mild to moderate AD or vascular dementia [12

Another experiment examined the effectiveness of long-term usage of Ginkgo biloba extract (120 mg), compared to placebo, for reducing the occurrence of AD in elderly people with memory complaints; nevertheless, the results revealed that the extract does not slow the course of AD [118, 119].

5.5 Resveratrol. The essential nonflavonoid resveratrol can be found in red wine, almonds, and grapes [120]. Resveratrol has a wide range of pharmacological activities, such as anti-inflammatory, antioxidant, anti-carcinogenic, and anti-mutagenic effects [121]. Neuroprotective benefits were also seen in AD in vitro and in vivo models. Resveratrol appears to have anti-inflammatory and antioxidant properties in addition to promoting nonamyloidogenic APP division and aiding in the removal of neurotoxic A peptides, all of which are critical for preventing and delaying the pathogenesis of AD [122]. Resveratrol also decreases the loss of neuronal cells via a number of mechanisms, including the activity of NAD+-dependent histone deacetylase enzymes known as sirtuins [123]. Resveratrol also acts as an antioxidant by decreasing the generation of ROS, increasing the amounts of GSH and intracellular Ca21 in neurons, and altering the action of cAMP and nitric oxide, which are second messengers [124]. Furthermore, it binds to A plaques, removing the A peptide and stopping the activity of AChE in in vitro cells [125].

6.Neuroprotective Mechanisms of Natural Products for AD

6.1Ant oxidative Neuroprotective Activity of Natural Products for AD. Both radical and nonradical oxidants are included in the extremely reactive molecules known as reactive nitrogen species (RNS) and reactive oxygen species (ROS). For procedures including cell cycle modulation, enzyme and receptor activation, inflammatory monitoring, phagocytosis, gene expression, and signal transmission, it is important to set up a controlled percentage of these oxidizing agents in the human body [126–129]. The nuclear factor E2-related factor 2 (Nrf2) pathway is one of the most widely used strategies for regulating these reactive species. In response to OS, the transcription factor Nrf2 increases the production of antioxidant genes. The antioxidant response element (ARE) actively lowers OS, inflammation, and many harmful residues [130]. Due to higher metabolic activity and cellular regeneration that is limited in the brain, OS has a stronger impact on the brain than other body organs [131]. Consequently, OS is widely acknowledged as a crucial component in the gradual degeneration of neuronal structure and decline in neuronal activity, one of the primary causes of NDDs, including AD [127]. Antioxidant treatments have been developed as AD neuroprotective drugs with much effort [132]. According to studies that have been published, OS plays a significant role in the development of AD, and antioxidants work to mitigate OS's detrimental effects [133]. Natural and synthetic antioxidants are divided into two categories based on the natural prevalence of each type, with antioxidant molecules derived from natural sources predominating. The most well-known natural antioxidants include carotenoids, flavonoids, and the vitamins A, C, and E. They all operate to stop an organism from decaying as a result of ROS. Many naturally occurring antioxidants come from plants, such as carotenoids and antioxidant vitamins, and have phenolic and polyphenolic chemical structures, including hydroxyl groups on their aromatic rings (s). Both as hydrogen atom donors and free radical scavengers, these chemical compounds demonstrated potent antioxidant activity [134]. Additionally, these phenolic and polyphenolic substances have an anti-oxidative due to their structural characteristics, especially the hydroxyl groups [135]. Flavonoids are

the most frequent polyphenolic compounds and exhibit a variety of antioxidant properties [136]. Dietary polyphenols also reduce neuronal degeneration and death by reducing ROS levels [137]. Phenolic compounds, which are substances that occur naturally, reduce chronic NDDs, such as AD. Polyphenolic compounds and their derivatives have recently received interest due to their abilities as neuroprotective agents for enhanced management of AD [132].

6.2 Antineuroinflammatory and Neuroprotective Activity of Natural Products for AD. A number of theories, including the A, tau, cholinergic, and inflammatory hypotheses, have been put out to explain this complex illness, even though the actual pathophysiological process underlying AD is still unknown [138]. The accumulation of A in the brain, a crucial component in the pathogenesis of AD, has been linked to neuro inflammatory in line with this [139]. Elevated levels of ROS, which also encourage microglial activation, nuclear factor kappa B (NF-B), and cytokine release, are a hallmark of the neuro inflammatory process in AD [140]. Proinflammatory cytokines including IFN-, IL-1, and TNF are also released when immune cells are activated, and these substances in turn encourage surrounding astrocytes to produce A-42 oligomers [141]. The cerebrospinal fluid, serum, and brains of AD patients have all revealed high concentrations of these proinflammatory cytokines [142]. In this regard, research has linked elevated cytokine levels over the whole course of the disease to memory loss in AD [143]. In particular in neurological diseases like AD, it is linked to brain function as well [144, 145]. It has been found in the brains of Alzheimer's patients [147], and it has been suggested that A-initiated neurotoxicity is associated with its activation [146]. Natural therapies help stop AD neurodegeneration and have fewer adverse effects than synthetic ones. Additionally, as a pharmaceutical intervention to lessen the early signs of AD, natural compounds with anti-inflammatory effects may be employed [148]. Numerous targets and signaling pathways are involved in the anti-inflammatory effects of these chemical substances. Natural products can also enhance the effects of ant amyloid as a sound output in the therapy of AD due to their ability to reduce neuro inflammatory [149]. It is important to investigate the multimarket anti-inflammatory effects of natural chemicals or combinations of natural goods as prospective therapeutic solutions for treating AD [150]. Table 1 provides a list of several plant-based natural extracts, chemicals, and mixtures that have neuroprotective properties.

6.2 Amyloid-β (Aβ) and Its Related Enzymes. The proteolytic processing of APP by - and -secretases results in the production of amyloid beta peptide (A) [226]. Published studies have shown that immunization against A reduces memory impairments in transgenic mice and has a neuroprotective impact without lowering the A plaque load [227, 228]. These results demonstrate that various forms of A in AD brains significantly contribute to neurotoxicity and that A in plaques may not directly cause synapse loss [229]. Consequently, a number of treatment trials involving passive and active vaccines against A were carried out [230] in light of the discovery that A plays a substantial role in the origin of AD. and vaccination campaigns against A were ongoing [230]. However, neither approach was effective enough to be used in clinical studies because of negative side effects like encephalitis and a lack of adequate therapy. A peptide builds up, which is involved in The actions of -secretase and site APPcleaving enzyme 1 (BACE1) on APP are crucial to the pathogenesis of AD. Prior to its detection, BACE1

activity has been found in cells and tissues [231]. The synthesis of APP regions that have been cleaved by A and BACE1 is, however, accelerated by overexpressing BACE1 [232]. This is due to the fact that BACE1 splits APP carrying the Swedish familial AD-causing mutation between ten and one hundred times more effectively than wild-type APP [231]. Additionally, antidrug testing has been done on a few BACE1 inhibitors [233]. Currently, early onset AD is primarily caused by gene mutations [234]. Presenilins are the aspartyl protease complexes that are membrane-implanted and create the carboxyl terminus of A from APP. Later research revealed that they are multipass membrane proteins that function as -secretase catalytic components [235]. The -secretase activity is the therapeutic target of medications that lower the amyloid plaque, whose buildup is thought to induce Alzheimer's disease (AD). In the interim, secretase, a crucial target for developing an AD therapy, is connected to notch signaling. To this end, numerous medicines that change A synthesis by -secretase without affecting Notch proteolysis and signaling are currently being investigated as potential treatments. It is significant to remember that the secretase modulator flurbiprofen was the first drug to go through a clinical trial. It was a failure, though, because the treatment proved ineffective. One such potent Notch sparing inhibitor that has just been identified and evaluated in several clinical trial phases is GSI-953 from Wyeth [236].

Glycogen Synthase Kinase 3 (GSK3) and Tau Protein. Tau is the primary protein interacting with microtubules in mature neurons (MAP). The pathophysiology of AD and other related illnesses known as tauopathies are significantly influenced by tau, which is accumulated in the affected brain regions [238]. In the AD brain, tau is three to four times more hyperphosphorylated than it is in the average adult brain. Alzheimer's disease (AD) pathologic tau is improperly cleaved and hyperphosphorylated [239]. In order to treat AD and other tauopathies, it may be beneficial to prevent aberrant tau hyperphosphorylation [228]. Recent studies have linked early structural changes in soluble tau proteins, notably their phosphorylation, to neurodegeneration [240, 241]. GSK3 may be a kinase that regulates tau aggregation in this situation by Additionally, research revealed that A increases tau phosphorylation and GSK3 activation in AD [243]. Several GSK3 inhibitors are presently being investigated for their potential as a treatment for AD. Additionally, studies showed that the GSK3 inhibitor AZD1080, which is potent and selective, can suppress tau phosphorylation in intact rat brain as well as in cells that express human tau [244].

7.1. Acetylcholine-Related Molecules. Cholinergic insufficiency brought on by basal forebrain atrophy was discovered in AD, in addition to the complicated clinical and metabolic abnormalities implicated in the neuronal symptoms of AD, such as the production of NFT and A aggregation [17]. Furthermore, the preferential loss of neurons expressing nAChRs causes a large decline in cerebral nAChR levels in AD [245]. Additionally, nicotinic ligands can protect neurons by stimulating nAChRs, which is important for the interaction of acetylcholine and nicotinic ligands with nAChRs [246].New substances have been created as a result to boost acetylcholine levels, directly stimulate nAChRs, and correct mental deficiencies while protecting neurons from A neurotoxicity [247]. As a result, specific nAChR agonis

acetylcholinesterase (AChE) inhibitors that restrict acetylcholine hydrolysis have been found [248]. AChE has emerged as a crucial therapy target for achieving clinical development in AD because cholinergic deficitis a permanent and early consequence of disease development [249].

Galantamine, rivastigmine, and donepezil are three of the four medications for treating AD that are now available on the market. Galantamine, a substance derived from common snowdrop and other Amaryllidaceous bulbs, has received approval from a number of countries to treat the signs of AD-associated senile dementia [250].

CHAPTER FOUR

RESULTS & DISCUSSION

Discussion

The most typical NDD is AD, which poses serious societal and economic problems. Because there are insufficient effective diagnostic and therapeutic methods, AD is having trouble overcoming treatment-related obstacles. In this article, a variety of bioactive substances and natural extracts are used to address the treatment and prevention of AD. Animal and marine sources have yielded a relatively limited number of molecules, making plants the main source of the vast majority of natural chemicals investigated up to this point. Given the complexity of AD, these chemical substances were linked to a variety of therapy modalities. But the neuroprotectiveness of natural chemicals depends on their ability to traverse the BBB.

Table 1. Neuroprotective status of some plant-based natural products, extracts, and mixtures.

Plant	Extract	Neuroprotective Outcomes	Study Model	Reference
Panax ginseng	Root extracts	Reduced Aβ formation and aggregation, inhibited AChE, restored synaptophysin and ChAT activity, and decreased Aβ formation and aggregation	In vitro, in vivo	[153-159]
Ginkgo biloba	Leaf extract	scavenged free radicals, averted the mitochondrial malfunction, activated the JNK and ERK pathways, and blocked neuronal death	In vivo	[160-162]
Pistacia vera	Kernel	Improved cognitive and motor deficits caused by inhibited	In vivo	[163]

		cisplatin or vincristine		
Phyllanthus emblica	Ethanol extract	Improved learning, memory, and antioxidant potential. Inhibited AChE activity	In vivo	[164]
Hibiscus sabdariffa	Anthocyanin-enriched extracts	Reduced memory impairment by decreasing STZ-induced neuroinflammation and amyloidogenesis	In vitro, In vivo	[165]
Spirulina maxima	Ethanol extract	Reduced hippocampus Aβ1–42, APP, and BACE1 expression levels, which reduced AChE activity, lowered hippocampal OS, and elevated BDNF levels	In vivo	[166-168]
Ishige foliacea	Phlorotannin-rich fraction	Lowered brain AChE activity, reduced OS, and activated the ERK-BDNF-CREB signaling pathway	In vivo	[169]
Juglans regia	Defatted protein	Lowered pro-inflammatory cytokine expression and AChE levels, extensively restored antioxidant enzyme levels, and reduced NF-κB expression	In vivo	[170-174]

Almond (*Prunus dulcis*)	Paste	Reduced AChE activity, lowered cholesterol and triglyceride levels, increased brain tryptophan monoamine levels and serotonergic turnover, and improved learning and memory	In vivo	[175-178]
Hazelnut (*Corylus avellana*)	Kernel	Improved memory, reduced anxiety, and lowered neuroinflammation and apoptosis	In vivo	[175, 179, 180]
Vitis vinifera	Juice, polyphenolic extract	Exhibited antioxidant, anti-neuroinflammatory, and anti-amnesic properties, and inhibited Aβ aggregation	In vivo	[181-186]
Oryza sativa	Dietary supplement	Reduced hippocampal AChE activity and lipid peroxidation products	In vivo	[187]
Zingiber officinale	Root extract	Acted as AChE inhibitor, suppressed lipid peroxidation, caused NMDA receptor overstimulation and inhibited the generation of free radicals	In vivo	[188, 189]
Benincasa hispida	Aqueous extract	Prevented substance P (SP) formation, as were antioxidant	In vivo	[190]

		scavenging effects		
Fuzhisan	Herbal complex	Exhibited anti-apoptosis and anti-Aβ buildup activity, increased ACh concentrations and provided neurotrophic benefits	In vivo	[191-194]
Bojungikgi-tang	Herbal formula	Prevented the accumulation and Aβ peptides expression, NeuN, and BDNF in the hippocampus by inhibiting the aggregation of Aβ, enhanced BACE activity in vivo, and increased antioxidant action	In vitro, In vivo	[195]
Pistacia integerrima	Gall extracts	Exhibited cholinesterase inhibitory and free radical scavenging activity	In vitro	[196]
Phyllanthus acidus	Methanol extract	Increased brain antioxidant enzymes, improved cognitive functioning, and reduced OS.	In vitro	[197],
Hedera nepalensis	Crude extract	Increased catalase (CAT) and superoxide dismutase (SOD) levels, and decreased glutathione	In vivo	[198]

		(GSH) levels		
Thalassospira profundimaris	Crude extract	Preserved the synaptic structure and prevented cell cycle-related neuron death	In vitro, in vivo	[199]
Eisenia bicycles	Methanol extract	Attenuated OS and reduced neuronal cell death	In vitro	[200]
Curcuma longa	Ethanol extract	Reduced CeCl3-induced OS, increased antioxidant enzyme activity, and inhibited AChE activity	In vitro, in vivo	[110, 201-207]
Allium sativum	Aged garlic extract	Reduced microglial activation and IL-1 levels and the inflammatory response, and reduced psychological stress via modulating stress hormones and the OS response in the brain.	In vivo	[208-211]
Momordica charanti	Dried and ground fruit	Reduced gliosis, oligomeric Aβ levels, tau hyperphosphorylation, and neuronal death. Increased synaptic-related protein and pS9-GSK3b expression levels	In vitro, In vivo	[190, 212]
Bacopa monnieri	Extract	Reduced cholinergic degeneration,	In vivo	[213-218]

		improved cognition, and suppressed AChE activity		
Viscum album	Extract	Significantly raised serum BDNF levels and reduced AlCl3-induced neurotoxicity	In vitro, In vivo	[219]
Pistacia Atlantica	Ethyl acetate and aqueous extracts	Inhibitory action of AChE	In vitro	[220]
Nardostachys jatamansi	Ethanol extract	Inhibited cell death caused by Aβ	In vitro, in vivo	[221, 222]
Phyllanthus amarus, ***Cynodon dactylon***	Methanol extract	Increased superoxide dismutase, catalase, and NADH dehydrogenase levels	In vivo	[223]
Salvia miltiorrhiza	Root extract	Inhibited OS and the mitochondria-dependent apoptotic pathway, inhibited production of NO and iNOS expression, induced neuron cell development in rat mesenchymal stem cells, and enhanced the differentiation ability of iPSCs and the survival and neuronal maturation of iPSC-derived neurons	In vitro, In vivo	[224-227]

transplanted.

Molecules found in marine and animal sources. These organic compounds were connected to a variety of therapy options because AD is a complicated illness. The ability of natural compounds to cross the BBB, however, determines how neuroprotective those molecules are. The difficulty of bridging the BBB and drug bioavailability are significant obstacles to the development of new therapies. Experimental and observational studies both demonstrate that bioactive compounds improve cognitive functioning in AD patients. Their different mechanisms of action result in a variety of positive outcomes, but the most important ones are the following: a decrease in A levels and tau phosphorylation rate, a reduction in A and tau aggregation, protection against OS, anti-inflammatory activity, preservation of cellular structures, and a reduction in neuronal apoptosis. The creation of potent and specific bioactive plant derivative natural compounds with favorable ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, particularly higher metabolic stability and lower toxicity, continues to be a difficult task for medicinal chemists despite recent significant discoveries. Thus, even if no novel natural molecule has been advanced to the stage of a clinical trial in several decades, bioactive compounds will probably remain on stage for a while. Clinical investigations should look into substances that have been found to have neuroprotective qualities in vivo.

7. Therapeutic Targets for AD

10.1 Amyloid-β (Aβ) and It's related Enzymes

The proteolytic processing of APP by - and -secretases results in the formation of amyloid beta peptide (A) [228]. According to published studies, immunization against A reduces memory deficits in transgenic mice without affecting the load of A plaques [229, 230]. These results demonstrate that alternative forms of A play a key role in neurotoxicity in AD brains and that A in plaques may not promote synapse degeneration [231]. In keeping with this, and in light of the evidence suggesting that A is a key contributor to the pathogenesis of AD, a number of treatment studies utilizing passive and active immunization against A were carried out [232]. However, due to adverse effects including encephalitis and insufficient treatment efficacy, neither strategy proved successful in clinical research.. The accumulation of A peptide, which plays a role in the pathophysiology of AD, depends on the action of -secretase and -site APP-cleaving enzyme 1 (BACE1) on APP. The BACE1 activity was already known to exist in cells and tissues [233]. On the other hand, overexpressing BACE1 promotes the synthesis of APP fragments that have been cleaved by A and BACE1 [234]. This is because, compared to wild-type APP, BACE1 splits APP

carrying the Swedish familial AD-causing mutation about ten to one hundred times more efficiently [233].

Additionally, certain BACE1 inhibitors have undergone antidrug testing [235]. Presenilin gene mutations are the root cause of AD with early onset [236]. Presenilins are multipass membrane proteins that were later identified as being catalytic elements of -secretase; these membrane-implanted aspartyl protease complexes produce the carboxyl terminus of A from APP [237]. Drugs that reduce amyloid plaque, whose buildup is considered to cause AD, have as their therapeutic target the activity of -secretase. In the meantime, the notch signaling is linked to -secretase, which is the main focus for creating an AD treatment. In this regard, a variety of drugs are currently being developed as potential therapeutics that modify A production by -secretase without altering Notch proteolysis and signaling. It is important to note that the first medication to undergo a clinical investigation was the -secretase modulator flurbiprofen. However, due to a lack of therapeutic effectiveness, it was a failure. GSI-953 from Wyeth is one example of the many strong Notch-sparing inhibitors that have recently been discovered

10.2 Tau Protein and Glycogen Synthase Kinase 3 (GSK3)

Tau is a mature neuron`s primary microtubule related protein (MAP). Tau is deposited withinside the diseased mind regions, and this performs a considerable position withinside the improvement of AD and different comparable disorders, which can be called tauopathies [240]. Tau is 3 to 4 instances greater hyperphosphorylated in AD mind than in healthful person mind. Pathologic tau in AD is abnormally cleaved and hyperphosphorylated [241]. Thus, stopping aberrant tau hyperphosphorylation is a probable healing goal for treating AD and different tauopathies [230]. Recent studies has linked neurodegeneration to early changes withinside the architectures of soluble tau proteins, specially their phosphorylation [242, 243]. In this context, GSK3 is a capability kinase that controls tau aggregation with the aid of using phosphorylating tau protein and controlling tau binding to microtubules, tau breakdown, and tau aggregation [244]. Additionally, studies found out that A will increase tau phosphorylation and GSK3 activation in AD [245]. Several GSK3 inhibitors are currently being investigated for his or her capability as a remedy for AD. Additionally, research have proven that the effective and unique GSK3 inhibitor AZD1080 can save you tau phosphorylation in each intact rat mind and cells that explicit human tau [246].

10.3 Molecules Related to Acetylcholine

In addition to the complicated scientific and metabolic troubles implicated withinside the neuronal signs and symptoms of AD, together with the formation of NFT and A aggregation, cholinergic insufficiency as a result of basal forebrain atrophy became discovered in AD [17]. Furthermore, cerebral nAChR tiers drastically lower in AD [247] due to the desired lack of

neurons expressing nAChRs. Additionally, acetylcholine and nicotinic ligands have interaction with nAChRs withinside the brain, and nicotinic ligand stimulation of nAChRs also can guard neurons [248]. In an attempt to opposite intellectual deficiencies and guard neurons from A neurotoxicity, new compounds were created to enhance acetylcholine tiers and immediately stimulate nAChRs [249]. As a result, precise nAChR agonists and acetylcholinesterase (AChE) inhibitors that limition acetylcholine hydrolysis were discovered [250]. AChE has emerged as a critical remedy goal for accomplishing scientific improvement in AD due to the fact cholinergic deficit is a continual and early . In this regard, 3 of the 4 capsules now available in the marketplace for the remedy of AD are galantamine, rivastigmine, and donepezil. A quantity of countries have authorized using galantamine, a compound crafted from the bulbs of not unusualplace snowdrops and unique Amaryllidaceae, to deal with the signs and symptoms of senile dementia related to AD [252].

8.Future Perspective

In conclusion, AD is a dreadful neurological ailment that has been plaguing human beings for an extended time. No drug or plant extract should successfully opposite the symptoms and symptoms of the disease, regardless of the truth that there are presently few prescribed drugs to be had for the remedy of AD and that many plant life and their extracts were applied substantially in animal research and AD patients [251-254]. AD is a multifactorial contamination with severa underlying causes. The modern treatments provide a few symptomatic alleviation, however they haven't any effect at the morbidity or mortality of the disease. They are primarily based totally on AChE inhibition or NMDA receptor antagonism. Because of those flaws, greater enormous studies is wanted to recognize the traits of NDDs, their ancient context, and proposed healing approaches. Combining herbal product chemistry, medicinal chemistry, pharmacology, biology, and different associated fields can be the simplest manner to discover new tablets and growth the probability that herbal merchandise and merchandise derived from herbal reassets can be advanced into prescribed drugs which might be therapeutically applicable for the remedy and prevention of AD. The use of nanotechnology and Nano carrier-primarily based totally transport strategies for herbal merchandise and their man or woman additives might also additionally enhance and growth the efficacy and effectiveness of healing reactions. The bioavailability of herbal merchandise and their additives may be progressed via way of means of using nanoparticles withinside the transport.

CHAPTER FIVE

CONCULATION

9.Conclusion

Decreased best of existence diet, and aging, must be taken into consideration in coping with AD. instances given the variety and complexity of the genetic and epigenetic elements underlying AD. Additionally, greater thorough and realistic best manipulate necessities protect the safety and effectiveness of those neuroprotective drugs. Additionally, novel strategies and techniques to boom CNS direct publicity to those neuroprotective compounds, inclusive of using nanotechnology to the switch of herbal products, can also additionally play a essential element in slowing the development of dementia. In conclusion, this evaluate has established how nature can each save you and deal with AD. In this respect, fruits, spices, nuts, and herbs incorporate essential bioactive chemical compounds that may assist save you and deal with diverse ailments, along with AD, without critical destructive aspect effects.

CHAPTER SIX
REFERENCE

References

[1] S. N. Rai, C. Singh, A. Singh, M. Singh, and B. K. Singh, “Mitochondrial dysfunction: a potential therapeutic target to treat Alzheimer’s disease,” Molecular Neurobiology, vol. 57, no. 7, pp. 3075–3088, 2020.

[2] W. J. Meilandt, H. Ngu, A. Gogineni et al., “Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the Aβ42: Aβ40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer's mouse model,” Journal of Neuroscience, vol. 40, no. 9, pp. 1956–1974, 2020.

[3] M. M. Essa, R. K. Vijayan, G. Castellano-Gonzalez, M. A. Memon, N. Braidy, and G. J. Guillemin, “Neuroprotective effect of natural products against Alzheimer’s disease,” Neurochemical Research, vol. 37, no. 9, pp. 1829–1842, 2012.

[4] W. Grodzicki and K. Dziendzikowska, “The role of selected bioactive compounds in the prevention of Alzheimer’s disease,” Antioxidants, vol. 9, no. 3, p. 229, 2020.

[5] X. Chen, J. Drew, W. Berney, and W. Lei, “Neuroprotective natural products for Alzheimer’s disease,” Cells, vol. 10, no. 6, article 1309, 2021.

[6] A.K.Singh,S.N.Rai,A.Mauryaetal.,“Therapeuticpotential of phytoconstituents inmanagementof Alzheimer’sdisease,” Evidence-based Complementary and Alternative Medicine, vol. 2021, Article ID 5578574, 19 pages, 2021.

[7] V. Chauhan and A. Chauhan, “Oxidative stress in Alzheimer's disease,” Pathophysiology, vol. 13, no. 3, pp. 195–208, 2000.

[8] S. N. Rai, N. Tiwari, P. Singh et al., “Therapeutic potential of vital transcription factors in alzheimer’s and parkinson’s disease with particular emphasis on transcription factor eb mediated autophagy,” Frontiers in Neuroscience, vol. 15, p. 1703, 2021

[9] N. Javaid, M. A. Shah, A. Rasul et al., “Neuroprotective effects of Ellagic acid in Alzheimer's disease: focus on underlying molecular mechanisms of therapeutic potential,” Current Pharmaceutical Design, vol. 27, no. 34, pp. 3591–3601, 2021.

[10] J. Brown, “Mutations in amyloid precursor protein gene and disease,” The Lancet, vol. 337, no. 8746, pp. 923-924, 1991.

[11] P. Srivastava, P. N. Tripathi, P. Sharma et al., “Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory,” European Journal of Medicinal Chemistry, vol. 163, pp. 116–135, 2019.

[12] O.A.OlajideandS.D.Sarker,“Anti-inflammatorystudieson Adenanthera pavonina seed extract,” Inflammopharmacology, vol. 12, no. 2, pp. 196–202, 2004.

[13] D. A. Butterfield, T. Reed, S. F. Newman, and R. Sultana, “Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment,” Free Radical Biology and Medicine, vol. 43, no. 5, pp. 658–677, 2007.

[14] E. Mariani, M. Polidori, A. Cherubini, and P. Mecocci, “Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview,” Journal of Chromatography B, vol. 827, no. 1, pp. 65–75, 2005.

[15] M. S. Uddin, A. A. Mamun, S. Takeda, M. S. Sarwar, and M.M.Begum,“Analyzingthechanceofdevelopingdementia among geriatric people: a cross-sectional pilot study in Bangladesh,” Psychogeriatrics, vol. 19, no. 2, pp. 87–94, 2019.

[16] H. J. Markowitsch and A. Staniloiu, “Memory, autonoetic consciousness, and the self,” Consciousness and cognition, vol. 20, no. 1, pp. 16–39, 2011.

[17] P. N. Tripathi, P. Srivastava, P. Sharma, A. Seth, P. Saraf, and S. K. Shrivastava, “Design, synthesis, and biological evaluation of ferulic acid based 1,3,4-oxadiazole hybrids as multifunctional therapeutics for the treatment of Alzheimer's disease,” Bioorganic Chemistry, vol. 95, p. 103506, 2020.

[18] J. Gregory, Y. V. Vengalasetti, D. E. Bredesen, and R. V. Rao, “Neuroprotective herbs for the management of Alzheimer’s disease,” Biomolecules, vol. 11, no. 4, 2021.

[19] A. Akter, F. Islam, S. Bepary et al., “CNS depressant activities of Averrhoa carambola leaves extract in thiopental-sodium model of Swiss albino mice: implication for neuromodulatory properties,” Biologia, vol. 77, 2022.

[20] D. O. Kennedy and E. L. Wightman, “Polyphenols and the human brain: plant “secondary metabolite” ecologic roles andendogenoussignalingfunctionsdrivebenefits,”Advances in Nutrition, vol. 5, no. 5, pp. 515–533, 2014.

[21] W.-H. Lee, C.-Y. Loo, M. Bebawy, F. Luk, R. S. Mason, and R. Rohanizadeh, “Neuron-to-microglia Crosstalk in Psychiatric Disorders,” Current Neuropharmacology, vol. 18, no. 2, pp. 84–86, 2020.

[22] M. M. Rahman, F. Islam, M. A. Anwar Parvez, G. M. Ashraf, M. F. Ullah, and M. Ahmed, “Citrus limonL. (lemon) seed extract shows neuro-modulatory activity in an in vivo thiopental-sodium sleep model by reducing the sleep onset and enhancing the sleep duration,” Journal of Integrative Neuroscience, vol. 21, no. 1, 2022.

[23] M. Rahman, M. Rahaman, M. Islam et al., “Role of phenolic compounds in human disease: current knowledge and future prospects,” Molecules, vol. 27, p. 233, 2021.

[24] M.AkramandA.Nawaz,“EffectsofmedicinalplantsonAlzheimer's disease and memory deficits,” Neural Regeneration Research, vol. 12, no. 4, pp. 660–670, 2017.

[25] S. Andrade, M. J. Ramalho, J. A. Loureiro, and M. D. C. Pereira, “ProductionandCharacterization of Chitooligosaccharides: Evaluation of Acute Toxicity, Healing, and AntiInflammatory Actions,” International Journal of Molecular Sciences, vol. 22, no. 19, 2021.

[26] M. J. Page, J. E. McKenzie, P. M. Bossuyt et al., “Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement,” Journal of Clinical Epidemiology, vol. 134, pp. 103–112, 2022.

[27] M.J.Page,J.E.McKenzie,P.M.Bossuytetal.,“ThePRISMA 2020 statement: an updated guideline for reporting systematic reviews,” International Journal of Surgery, vol. 88, article 105906, 2021.

[28] A. Serrano-Pozo, M. P. Frosch, E. Masliah, and B. T. Hyman, “Neuropathological alterations in Alzheimer disease,” Cold Spring Harbor Perspectives in Medicine, vol. 1, no. 1, 2011.

[29] J.A.Schneider,Z.Arvanitakis,S.E.Leurgans,andD.A.Bennett, “Three faces of the same gene: FA2H links neurodegeneration with brain iron accumulation, leukodystrophies, and hereditary spastic paraplegias,” Annals of Neurology, vol. 68, no. 5, pp. 575–577, 2010.

[30] T. Revesz, J. McLaughlin, M. Rossor, and P. Lantos, “Pathology of Familial Alzheimer’s Disease with Lewy Bodies,” in Dementia in Parkinsonism, pp. 121–135, Springer, 1997.

[31] B.D.James,R.S.Wilson,P.A.Boyle,J.Q.Trojanowski,D.A. Bennett, and J. A. Schneider, “TDP-43 stage, mixed pathologies,andclinicalAlzheimer’s-typedementia,”Brain,vol.139, no. 11, pp. 2983–2993, 2016.

[32] Z. J. Fan and I. Aditya, “Obesity and Alzheimer’s disease: a bridge between two worlds,” The Meducator, vol. 1, no. 25, 2014.

[33] M. Ingelsson, H. Fukumoto, K. Newell et al., “Early A accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain,” Neurology, vol. 62, no. 6, pp. 925– 931, 2004.

[34] R. J. Hodes, N. Buckholtz, V. Cahan, and M. MorrisonBogorad, “Eyes on the prize: Federal Alzheimer’s research effort aims to facilitate interventions,” Alzheimer's & Dementia, vol. 4, no. 1S1, pp. S37–S47, 2008.

[35] X. Du, X. Wang, and M. Geng, “Alzheimer’s disease hypothesis and related therapies,” Translational Neurodegeneration, vol. 7, no. 1, 2018.

[36] P. Sharma, P. Srivastava, A. Seth, P. N. Tripathi, A. G. Banerjee, and S. K. Shrivastava, “Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies,” Progress in Neurobiology, vol. 174, pp. 53–89, 2019.

[37] J.W.Kinney,S.M.Bemiller,A.S.Murtishaw,A.M.Leisgang, A. M. Salazar, and B. T. Lamb, “Inflammation as a central mechanisminAlzheimer'sdisease,”Alzheimer's&Dementia: Translational Research & Clinical Interventions, vol. 4, pp. 575–590, 2018.

[38] P.dosSantos,C.Leide,P.F.Ozelaetal.,“Alzheimer'sdisease: areviewfromthepathophysiologytodiagnosis,newperspectives for pharmacological treatment,”

[39] J. Cummings, G. Lee, A. Ritter, and K. Zhong, “Alzheimer's disease drug development pipeline: 2018,” Alzheimer's & Dementia: Translational Research & Clinical Interventions, vol. 4, no. 1, pp. 195–214, 2018.

[40] J. S. Birks and R. J. Harvey, “Donepezil for dementia due to Alzheimer's disease,” Cochrane Database of systematic reviews, vol. 25, 2006.

[41] R. A. Bekdash, “The cholinergic system, the adrenergic system and the neuropathology of alzheimer’s disease,” International Journal of Molecular Sciences, vol. 22, no. 3, 2021.

[42] Y. Jiang, H. Gao, and G. Turdu, “Azaphilone derivatives with anti-inflammatory activity from the mangrove endophytic fungus Penicillium sclerotiorum ZJHJJ-18,” Bioorganic Chemistry, vol. 122, p. 105721, 2022.

[43] O. B. Villaflores, Y.-J. Chen, C.-P. Chen, J.-M. Yeh, and T.Y. Wu, “Curcuminoids and resveratrol as anti-Alzheimer agents,” Taiwanese Journal of Obstetrics and Gynecology, vol. 51, no. 4, pp. 515–525, 2012.

[44] A. J. Lin, M. A. Koike, K. N. Green et al., “Spatial frequency domain imaging of intrinsic optical property contrast in a mouse model of Alzheimer’s disease,” Annals of biomedical engineering, vol. 39, no. 4, pp. 1349–1357, 2011.

[45] R.E.Tanzi andL.Bertram, “TwentyYearsof theAlzheimer's Disease Amyloid Hypothesis: A Genetic Perspective,” Cell, vol. 120, no. 4, pp. 545–555, 2005.

[46] R. Jakob-Roetne and H. Jacobsen, “Alzheimer's disease: from pathology to therapeutic approaches,” Angewandte Chemie International Edition, vol. 48, no. 17, pp. 3030–3059, 2009.

[47] M. G. Savelieff, G. Nam, J. Kang, H. J. Lee, M. Lee, and M. H. Lim,“Developmentofmultifunctional moleculesaspotential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the last decade,” Chemical Reviews, vol. 119, no. 2, pp. 1221–1322, 2019.

[48] Z.Qu,V.V.Mossine,J.Cui,G.Y.Sun,andZ.Gu,“Protective effects of AGE and its components on neuroinflammation and neurodegeneration,” Neuromolecular medicine, vol. 18, no. 3, pp. 474–482, 2016.

[49] J.-y. Min and K.-b. Min, “Association between exposure to traffic-related air pollution and pediatric allergic diseases based on modeled air pollution concentrations and traffic measures in Seoul, Korea: a comparative analysis,” Environmental Health, vol. 19, no. 1, 2020.

[50] C. Sharma and S. R. Kim, “Relationship between Vitamin C Deficiency and Cognitive Impairment in Older Hospitalised Patients: A Cross-Sectional Study,” Antioxidants, vol. 11, no. 3, 2022.

[51] P.Faller,C.Hureau,andO.Berthoumieu,“Roleofmetalions in the self-assembly of the Alzheimer’s amyloid-β peptide,” Inorganic Chemistry, vol. 52, no. 21, pp. 12193–12206, 2013.

[52] N. Binjhade, V. Supare, S. Ghaywat, S. Trivedi, K. Wadher, and M. Umekar, “Agmatine: a potential Neurotherapeutic Agent,” Journal of Drug Delivery and Therapeutics, vol. 11, no. 4, pp. 88–92, 2021.

[53] R. C. Lajmanovich, A. M. Attademo, G. Lener et al., “Glyphosateandglufosinateammonium,herbicidescommonlyused on genetically modified crops, and their interaction with microplastics: ecotoxicity in anuran tadpoles,” Science of The Total Environment, vol. 804, article 150177, 2022.

[54] D. J. Bonda, H.-g. Lee, J. A. Blair, X. Zhu, G. Perry, and M. A. Smith, “Role of metal dyshomeostasis in Alzheimer's disease,” Metallomics, vol. 3, no. 3, pp. 267–270, 2011.

[55] M. A. Greenough, J. Camakaris, and A. I. Bush, “Metal dyshomeostasis and oxidative stress in Alzheimer's disease,” Neurochemistry International, vol. 62, no. 5, pp. 540–555, 2013.

[56] C. M. Cheignon, M. Tomas, D. Bonnefont-Rousselot, P. Faller, C. Hureau, and F. Collin, “Oxidative stress and the amyloid beta peptide in Alzheimer's disease,” Redox Biology, vol. 14, pp. 450–464, 2018.

[57] R. Sultana and D. A. Butterfield, “Redox proteomics studies ofinvivoamyloidbeta-peptideanimalmodelsofAlzheimer's disease: insight into the role of oxidative stress,” Proteomics Clinical Applications, vol. 2, no. 5, pp. 685–696, 2008.

[58] J.-M. Zhuo, G. S. Portugal, W. D. Kruger, H. Wang, T. J. Gould,andD.Praticò,“Diet-inducedhyperhomocysteinemia increases Amyloid-β formation and deposition in a mouse model of Alzheimers disease,” Current Alzheimer Research, vol. 7, no. 2, pp. 140–149, 2010.

[59] J.-M. Zhuo, H. Wang, and D. Praticò, “Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?,” Trends in Pharmacological Sciences, vol. 32, no. 9, pp. 562–571, 2011.

[60] O. Rabal, J. A. Sánchez-Arias, M. Cuadrado-Tejedor et al., “Design, synthesis, and biological evaluation of first-in-class dual acting histone deacetylases (HDACs) and phosphodiesterase 5

(PDE5) inhibitors for the treatment of Alzheimer's disease," Journal of Medicinal Chemistry, vol. 59, no. 19, pp. 8967–9004, 2016.

[61] W. B. Grant, "Using multicountry ecological and observational studies to determine dietary risk factors for Alzheimer's disease," Journal of the American College of Nutrition, vol. 35, no. 5, pp. 476–489, 2016.

[62] N.AnsariandF.Khodagholi,"Naturalproductsaspromising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect," Current Neuropharmacology, vol. 11, no. 4, pp. 414–429, 2013.

[63] N. M. Chitre, N. H. Moniri, and K. S. Murnane, "Omega-3 fatty acids as druggable therapeutics for neurodegenerative disorders," CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), vol. 18, no. 10, pp. 735–749, 2019.

[64] T. Silva, J. Reis, J. Teixeira, and F. Borges, "Alzheimer's disease, enzyme targets and drug discovery struggles: from natural products to drug prototypes," Ageing Research Reviews, vol. 15, pp. 116–145, 2014.

[65] P. Williams, A. Sorribas, and M.-J. R. Howes, "Employing chemicalsynthesistostudythestructureandfunctionofcolibactin, a dark matter metabolite," Natural Product Reports, vol. 37, no. 11, pp. 1532–1548, 2020.

[66] A. Bhattacharjee, A. Ramakrishna, M. Obulesu, A. Bhattacharjee, and A. Ramakrishna, "Plant Alkaloids and TheirDerivativesRelevanttoAlzheimer'sDisease,"inPhytomedicine and Alzheimer's Disease, pp. 271–284, CRC Press, 2020.

[67] M.I.Lazarova,D.S.Tsekova,L.P.Tanchevaetal.,"Newgalantamine derivatives with inhibitory effecton acetylcholinesterase activity," Journal of Alzheimer's Disease, vol. 83, no. 3, pp. 1211–1220, 2021.

[68] M. Heinrich and H. L. Teoh, "Best practice in research Overcoming common challenges in phytopharmacological research," Journal of Ethnopharmacology, vol. 246, p. 112230, 2020.

[69] J.Choueiry,C.M.Blais,D.Shahetal.,"CDP-cholineandgalantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study," Psychopharmacology, vol. 237, no. 12, pp. 3665–3687, 2020.

[70] E. Simoni, S. Daniele, G. Bottegoni et al., "Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease," Journal of Medicinal Chemistry, vol. 55, no. 22, pp. 9708–9721, 2012.

[71] M. Atanasova, G. Stavrakov, I. Philipova, D. Zheleva, N. Yordanov, and I. Doytchinova, "Galantamine derivatives withindole moiety:docking, design, synthesis and acetylcholinesterase inhibitory activity," Bioorganic & Medicinal Chemistry, vol. 23, no. 17, pp. 5382–5389, 2015.

[72] S. D. Upadhyay, Y. Ahmad, R. K. Sharma, and S. Kohli, "Huperzinea: pharmacological and therapeutic potential," Pharmacognosy Communications, vol. 10, no. 4, pp. 146– 149, 2020.

[73] X.-D.Wu,X.-N.Li,L.-Y.Peng,andQ.-S.Zhao,"HuperserratinesAandB,twoMacrocyclicLycopodiumAlkaloidswithan unusual skeleton fromHuperzia serrata," The Journal of Organic Chemistry, vol. 85, no. 10, pp. 6803–6807, 2020.

[74] Y.-f. Shi, H.-y. Zhang, W. Wang et al., "Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors," Acta Pharmacologica Sinica, vol. 30, no. 8, pp. 1195–1203, 2009.

[75] S. Mak, W. Li, H. Fu et al., "Promising tacrine/huperzine Abased dimeric acetylcholinesterase inhibitors for neurodegenerative disorders: From relieving symptoms to modifying diseases through multitarget," Journal of Neurochemistry, vol. 158, no. 6, pp. 1381–1393, 2021.

[76] S. Dietrich, J. Hüllein, M. Hundemer et al., "Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia," Journal of Clinical Oncology, vol. 31, no. 19, pp. e300–e303, 2013.

[77] J. Yan, L. Sun, G. Wu et al., “Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives,” Bioorganic & Medicinal Chemistry, vol. 17, no. 19, pp. 6937–6941, 2009.

[78] E. Viayna, I. Sola, M. Bartolini et al., “Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents,” Journal of Medicinal Chemistry, vol. 57, no. 6, pp. 2549–2567, 2014.

[79] M.ImanshahidiandH.Hosseinzadeh,“Pharmacologicaland therapeuticeffectsof Berberisvulgarisanditsactiveconstituent, berberine,” Phytotherapy Research, vol. 22, no. 8, pp. 999–1012, 2008.

[80] H. A. Jung, B.-S. Min, T. Yokozawa, J.-H. Lee, Y. S. Kim, and J.S.Choi,“Anti-AlzheimerandantioxidantactivitiesofCoptidis Rhizoma alkaloids,” Biological and Pharmaceutical Bulletin, vol. 32, no. 8, pp. 1433–1438, 2009.

[81] E. Küpeli, M. Koşar, E. Yeşilada, and K. H. C. Başer, “A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish _Berberis_ species,” Life Sciences, vol. 72, no. 6, pp. 645–657, 2002.

[82] S. S. K. Durairajan, L.-F. Liu, J.-H. Lu et al., “Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model,” Neurobiology of Aging, vol. 33, no. 12, pp. 2903–2919, 2012.

[83] S. Kulkarni and A. Dhir, “Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders,” Phytotherapy Research, vol. 24, no. 3, pp. 317–324, 2010.

[84] A.Shi,L.Huang,C.Lu,F.He,andX.Li,“Synthesis,biological evaluation andmolecular modeling of novel triazole containing berberine derivatives as acetylcholinesterase and β-amyloid aggregation inhibitors,” Bioorganic & Medicinal Chemistry, vol. 19, no. 7, pp. 2298–2305, 2011.

[85] T. Su, S. Xie, H. Wei, J. Yan, L. Huang, and X. Li, “Synthesis and biological evaluation of berberine-thiophenyl hybrids as multi- functional agents: Inhibition of acetylcholinesterase,

butyrylcholinesterase, and Aβ aggregation and antioxidant activity," Bioorganic & Medicinal Chemistry, vol. 21, no. 18, pp. 5830–5840, 2013.

[86] H. Tang,F.-X. Ning,Y.-B.Wei etal.,"Derivatives of oxoisoaporphine alkaloids: a novel class of selective acetylcholinesterase inhibitors," Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 13, pp. 3765–3768, 2007.

[87] H. Tang, Y.-B. Wei, C. Zhang et al., "Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphinederivativesasnewdualinhibitorsofacetylcholinesterase/butyrylcholinesterase," European Journal of Medicinal Chemistry, vol. 44, no. 6, pp. 2523–2532, 2009.

[88] E. Himeno, Y. Ohyagi, L. Ma et al., "Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation," Annals of Neurology, vol. 69, no. 2, pp. 248–256, 2011.

[89] H. Tang, L.-Z. Zhao, H.-T. Zhao et al., "Hybrids of oxoisoaporphine-tacrine congeners: Novel acetylcholinesterase and acetylcholinesterase-induced β -amyloid aggregation inhibitors,"EuropeanJournalofMedicinalChemistry,vol.46, no. 10, pp. 4970–4979, 2011.

[90] Z. Yang, Z. Song, W. Xue et al., "Synthesis and structure–activityrelationshipofnuciferinederivativesaspotentialacetylcholinesterase inhibitors," Medicinal Chemistry Research, vol. 23, no. 6, pp. 3178–3186, 2014.

[91] A. Panche, A. Diwan, and S. Chandra, "Flavonoids: an overview," Journal of Nutritional Science, vol. 5, p. e47, 2016.

[92] K. R. Rengasamy, H. Khan, S. Gowrishankar et al., "The role of flavonoids in autoimmune diseases: therapeutic updates," Pharmacology & Therapeutics, vol. 194, pp. 107–131, 2019.

[93] I. Cruz, P. Puthongking, S. Cravo et al., "Xanthone and flavonederivativesasdualagentswithacetylcholinesteraseinhibition and antioxidant activity as potential anti-alzheimer agents," Journal of Chemistry, vol. 2017, Article ID 8587260, 16 pages, 2017.

[94] F. Li, J.-J. Wu, J. Wang et al., “Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease,” Bioorganic & Medicinal Chemistry, vol. 25, no. 14, pp. 3815–3826, 2017.

[95] R.-S. Li, X.-B. Wang, X.-J. Hu, and L.-Y. Kong, “Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer’s disease,” Bioorganic & Medicinal Chemistry Letters, vol. 23, pp. 2636–2641, 2013.

[96] W. Luo, Y.-B. Su, C. Hong et al., “Design, synthesis and evaluation of novel 4-dimethylamine flavonoid derivatives as potential multi-functional anti-Alzheimer agents,” Bioorganic & Medicinal Chemistry, vol. 21, no. 23, pp. 7275– 7282, 2013.

[97] Y. Shen, J. Zhang, R. Sheng et al., “Synthesis and biological evaluation of novel flavonoid derivatives as dual binding acetylcholinesterase inhibitors,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 24, no. 2, pp. 372–380, 2009.

[98] R. Sheng, X. Lin, J. Zhang et al., “Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors,” Bioorganic & Medicinal Chemistry, vol. 17, no. 18, pp. 6692–6698, 2009.

[99] M. Singh, M. Kaur, N. Singh, and O. Silakari, “Corrigendum to Exploration of multi-target potential of chromen-4-one based compounds in Alzheimer's disease: Design, synthesis and biological evaluations,” Bioorganic & Medicinal Chemistry, vol. 26, no. 14, pp. 4360-4361, 2018.

[100] M. Singh and O. Silakari, “Design, synthesis and biological evaluation of novel 2-phenyl-1-benzopyran-4-one derivatives as potential poly-functional anti-Alzheimer's agents,” RSC Advances, vol. 6, no. 110, pp. 108411–108422, 2016.

[101] B. Feng, X. Li, J. Xia, and S. Wu, “Discovery of novel isoflavone derivatives as AChE/BuChE dual-targeted inhibitors: synthesis, biological evaluation and molecular modelling,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 32, no. 1, pp. 968–977, 2017.

[102] K. Duan, H. Liu, H. Fan, J. Zhang, and Q. Wang, “Synthesis and anticholinesterase inhibitory activity of Mannich base derivatives of flavonoids,” Journal of Chemical Research, vol. 38, no. 7, pp. 443–446, 2014.

[103] M.Y.Fosso,H.LeVine3rd,K.D.Green,O.V.Tsodikov,and S.Garneau-Tsodikova,“Effectsofstructuralmodificationson the metal binding, anti-amyloid activity, and cholinesterase inhibitory activity of chalcones,” Organic & Biomolecular Chemistry, vol. 13, no. 36, pp. 9418–9426, 2015.

[104] H.-r. Liu, X.-j. Liu, H.-q. Fan, J.-j. Tang, X.-h. Gao, and W.K. Liu, “Design, synthesis and pharmacological evaluation of chalcone derivatives as acetylcholinesterase inhibitors,” Bioorganic & Medicinal Chemistry, vol. 22, no. 21, pp. 6124–6133, 2014.

[105] G. Xiao, Y. Li, X. Qiang et al., “Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease,” Bioorganic & Medicinal Chemistry, vol. 25, no. 3, pp. 1030–1041, 2017.

[106] S.-S. Xie, X.-B. Wang, J.-Y. Li, L. Yang, and L.-Y. Kong, “Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease,” European Journal of Medicinal Chemistry, vol. 64, pp. 540–553, 2013.

[107] A. Saeed, S. Zaib, S. Ashraf et al., “Synthesis, cholinesterase inhibition and molecular modelling studies of coumarin linked thiourea derivatives,” Bioorganic Chemistry, vol. 63, pp. 58–63, 2015.

[108] M. Ganguli, V. Chandra, M. I. Kamboh et al., “Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US cross-national dementia study,” Archives of Neurology, vol. 57, no. 6, pp. 824–830, 2000.

[109] D. Lobine, N. Sadeer, S. Jugreet et al., “Potential of medicinal plants as neuroprotective and therapeutic properties against amyloid-β-related toxicity, and glutamate-induced excitotoxicity in human neural cells,” Current Neuropharmacology, vol. 19, no. 9, pp. 1416–1441, 2021.

[110] P. Tagde, P. Tagde, F. Islam et al., “The multifaceted role of curcumin in advanced nanocurcumin form in the treatment and management of chronic disorders,” Molecules, vol. 26, no. 23, p. 7109, 2021.

[111] M. Chen, Z.-Y. Du, X. Zheng, D.-L. Li, R.-P. Zhou, and K. Zhang, “Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease,” Neural Regeneration Research, vol. 13, no. 4, pp. 742–752, 2018.

[112] M. Rahman, S. Majumder, F. Akter, F. Islam, M. Shahriar, and J. Alam, “Pre-clinical investigation of analgesic, antidiarrheal and CNS depressant effect of Pterocarpus indicus in Swiss albino mice,” Jordan Journal of Pharmaceutical Sciences, vol. 14, no. 1, 2021.

[113] R. H. Alattiya, F. K. Tarish, L. L. Hashim, and S. A. Hussain, “The role of polyphenols in the treatment of Alzheimer's disease: curcumin as a prototype: polyphenols in Alzheimer's disease,” Al-Rafidain Journal of Medical Sciences, vol. 1, pp. 53–61, 2021.

[114] P.Khare,A.K.Datusalia,andS.S.Sharma,“Parthenolide,an NF-κB inhibitor ameliorates diabetes-induced behavioural deficit, neurotransmitter imbalance and neuroinflammation in type 2 diabetes rat model,” Neuromolecular Medicine, vol. 19, no. 1, pp. 101–112, 2017.

[115] C. Zhu, Z. Xiong, X. Chen et al., “Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-κB pathway in microglia cells,” PLoS One, vol. 7, no. 4, 2012.

[116] V. Navaratnam, S. M. Mansor, N.-W. Sit, J. Grace, Q. Li, and P. Olliaro, “Pharmacokinetics of artemisinin-type compounds,” Clinical Pharmacokinetics, vol. 39, no. 4, pp. 255– 270, 2000.

[117] M. R. de Oliveira, “The dietary components carnosic acid and carnosol as neuroprotective agents: a mechanistic view,” Molecular Neurobiology, vol. 53, no. 9, pp. 6155– 6168, 2016.

[118] B.Vellas,N.Coley,P.-J.Oussetetal.,“Long-termuseofstandardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial,” The Lancet Neurology, vol. 11, no. 10, pp. 851–859, 2012.

[119] Y. Zhang, Q. Huang, S. Wang et al., “The Food Additive βCaryophyllene Exerts Its Neuroprotective Effects Through the JAK2-STAT3-BACE1 Pathway,” Frontiers in Aging Neuroscience, vol. 14, 2022.

[120] Z. Liang, C. L. Owens, G.-Y. Zhong, and L. Cheng, “Polyphenolic profiles detected in the ripe berries of Vitis vinifera germplasm,” Food Chemistry, vol. 129, no. 3, pp. 940–950, 2011.

[121] C. Alarcon De La Lastra and I. Villegas, “Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications,” Molecular Nutrition & Food Research, vol. 49, no. 5, pp. 405–430, 2005.

[122] N. Braidy, B.-E. Jugder, A. Poljak et al., “Resveratrol as a potential therapeutic candidate for the treatment and managementofAlzheimer’sdisease,”CurrentTopicsinMedicinal Chemistry, vol. 16, no. 17, pp. 1951–1960, 2016.

[123] J.Schemies,U.Uciechowska,W.Sippl,andM.Jung,“NAD+dependent histone deacetylases (sirtuins) as novel therapeutic targets,” Medicinal Research Reviews, vol. 30, no. 6, pp. 861–889, 2010.

[124] F. Li, Q. Gong,H. Dong, andJ. Shi, “Resveratrol, a neuroprotective supplement for Alzheimer's disease,” Current Pharmaceutical Design, vol. 18, no. 1, pp. 27–33, 2012.

[125] E. O. Lee, H. J. Park, J. L. Kang, H. S. Kim, and Y. H. Chong, “Resveratrol reduces glutamate-mediated monocyte chemotactic protein-1 expression via inhibition of extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1477–1487, 2010.

[126] T. Hussain, B. Tan, Y. Yin, F. Blachier, M. C. Tossou, and N. Rahu, “Oxidative stress and inflammation: what polyphenolscandoforus?,”OxidativeMedicineandCellularLongevity, vol. 2016, Article ID 7432797, 9 pages, 2016.

[127] M. T. Islam, “Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders,” Neurological Research, vol. 39, no. 1, pp. 73–82, 2017.

[128] S. Manoharan, G. J. Guillemin, R. S. Abiramasundari, M. M. Essa, M. Akbar, and M. D. Akbar, “The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: a mini review,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 8590578, 15 pages, 2016.

[129] Z.Liu,T.Zhou,A.C.Ziegler,P.Dimitrion,andL.Zuo,“Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications,” Oxidative Medicine andCellularLongevity,vol.2017,ArticleID428010,11pages, 2017.

[130] A. Otsuki and M. Yamamoto, “Cis-element architecture of Nrf2–sMaf heterodimer binding sites and its relation to diseases,” Archives of Pharmacal Research, vol. 43, no. 3, pp. 275–285, 2020.

[131] I. Liguori, G. Russo, F. Curcio et al., “Oxidative stress, aging, and diseases,” Clinical Interventions in Aging, vol. 13, p. 757, 2018.

[132] R. I. Teleanu, C. Chircov, A. M. Grumezescu, A. Volceanov, and D. M. Teleanu, “Antioxidant therapies for neuroprotection a review,” Journal of Clinical Medicine, vol. 8, no. 10, p. 1659, 2019.

[133] G. Juszczyk, J. Mikulska, K. Kasperek, D. Pietrzak, W. Mrozek, and M. Herbet, “Chronic stress and oxidative stress as common factors of the pathogenesis of depression and Alzheimer’s disease: the role of antioxidants in prevention and treatment,” Antioxidants, vol. 10, no. 9, p. 1439, 2021.

[134] R. Chandran, T. Sajeesh, and T. Parimelazhagan, “Total phenoliccontent,anti-radicalpropertyandHPLCprofilesofCaralluma diffusa(Wight) N.E. Br,” Journal of Biologically Active Products from Nature, vol. 4, no. 3, pp. 188–195, 2014.

[135] P. Cosme, A. B. Rodríguez, J. Espino, and M. Garrido, “Plant phenolics:Bioavailabilityasakeydeterminantoftheirpotential health-promoting applications,” Antioxidants, vol. 9, no. 12, 2020.

[136] S. Kumar and A. K. Pandey, “Chemistry and biological activitiesof flavonoids:anoverview,”TheScientificWorldJournal, vol. 2013, Article ID 162750, 16 pages, 2013.

[137] V. Calabrese, D. A. Butterfield, and A. Stella, “Nutritional antioxidantsandthehemeoxygenasepathwayofstresstolerance: novel targets for neuroprotection in Alzheimer's disease,” The Italian journal of biochemistry, vol. 52, no. 4, pp. 177–181, 2003.

[138] K. G. Yiannopoulou and S. G. Papageorgiou, “Current and future treatments for Alzheimer’s disease,” Therapeutic Advances in Neurological Disorders, vol. 6, no. 1, pp. 19–33, 2013.

[139] I. D. Prà, A. Chiarini, L. Gui et al., “Do astrocytes collaborate with neurons in spreading the “infectious” Aβ and Tau drivers of Alzheimer’s disease?,” The Neuroscientist, vol. 21, no. 1, pp. 9–29, 2015.

[140] R. Von Bernhardi, F. Cornejo, G. Parada, and J. Eugenín, “Role of TGFβ signaling in the pathogenesis of Alzheimer’s disease,” Frontiers in Cellular Neuroscience, vol. 9, p. 426, 2015.

[141] M.-S. Tan, J.-T. Yu, T. Jiang, X.-C. Zhu, and L. Tan, “The NLRP3 inflammasome in Alzheimer’s disease,” Molecular Neurobiology, vol. 48, no. 3, pp. 875–882, 2013.

[142]D.S.SimpsonandP.L.Oliver,“ROSgenerationinmicroglia:understandingoxidativestressandinflammationinneurodegenerative disease,” Antioxidants, vol. 9, no. 8, p. 743, 2020.

[143] M. L. Garcez, F. Mina, T. Bellettini-Santos et al., “Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid β (1-42) in mice,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 77, pp. 23–31, 2017.

[144] M. Sandberg, J. Patil, B. D'Angelo, S. G. Weber, and C. Mallard, “NRF2-regulation in brain health and disease: implication of cerebral inflammation,” Neuropharmacology, vol. 79, pp. 298–306, 2014.

[145] M. Yu, H. Li, Q. Liu et al., “Nuclear factor p65 interacts with Keap1torepresstheNrf2-ARElpathway,”CellularSignalling, vol. 23, no. 5, pp. 883–892, 2011.

[146] F. Longpré, P. Garneau, and C. Ramassamy, “Protection by EGb 761 against β-amyloid-induced neurotoxicity: involvement of NF-κB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation,” Free Radical Biology and Medicine, vol. 41, no. 12, pp. 1781–1794, 2006.

[147] M. S. Uddin, S. Hasana, J. Ahmad et al., “Anti-neuroinflammatory potential of polyphenols by inhibiting NF-κB to halt Alzheimer's disease,” Current Pharmaceutical Design, vol. 27, no. 3, pp. 402–414, 2021.

[148] E. L. Cooper and M. J. Ma, “Alzheimer disease: clues from traditional and complementary medicine,” Journal of Traditional and Complementary Medicine, vol. 7, no. 4, pp. 380– 385, 2017.

[149] L. Zhao, J.-L. Wang, R. Liu, X.-X. Li, J.-F. Li, and L. Zhang, “Neuroprotective, anti-amyloidogenic and neurotrophic effects of apigenin in an Alzheimer’s disease mouse model,” Molecules, vol. 18, no. 8, pp. 9949–9965, 2013.

[150] K. A. Wollen, “Alzheimer’s disease: the pros and cons of pharmaceutical,nutritional,botanical,andstimulatorytherapies, with a discussion of treatment strategies from the perspective of patients and practitioners,” Altern Med Rev, vol. 15, no. 3, pp. 223–244, 2010.

[151] J.-S. Seo, J.-H. Yun, I.-S. Baek et al., “Oriental medicine Jangwonhwan reduces Aβ (1–42) level and β-amyloid deposition in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease,” Journal of Ethnopharmacology, vol. 128, no. 1, pp. 206–212, 2010.

[152] J. Kim, S. H. Kim, D.-S. Lee, S. H. Kim, S. Chung, and H. O. Yang, “Effects of fermented ginseng on memory impairment and β-amyloid reduction in Alzheimer’s disease experimental models,” Journal of Ginseng Research, vol. 37, no. 1, p. 100, 2013.

[153] J. G. Choi, N. Kim, E. Huh et al., “White ginseng protects mouse hippocampal cells against amyloid-beta oligomer toxicity,” Phytotherapy Research, vol. 31, no. 3, pp. 497–506, 2017.

[154] J.-H. Heo, S.-T. Lee, M. J. Oh et al., “Improvement of cognitive deficit in Alzheimer’s disease patients by long term treatment with Korean red ginseng,” Journal of Ginseng Research, vol. 35, no. 4, p. 457, 2011.

[155] J.-H. Heo, M.-H. Park, and J.-H. Lee, “Effect of Korean red ginseng on cognitive function and quantitative EEG in patients with Alzheimer's disease: a preliminary study,” The Journal of Alternative and Complementary Medicine, vol. 22, no. 4, pp. 280–285, 2016.

[156] H.-J. Kim, S.-W. Jung, S.-Y. Kim et al., “Panax ginseng as an adjuvant treatment for Alzheimer's disease,” Journal of Ginseng Research, vol. 42, no. 4, pp. 401–411, 2018.

[157] M. R. Lee, B. S. Yun, O. H. In, and C. K. Sung, “Comparative studyofKoreanwhite,red,andblackginsengextractoncholinesteraseinhibitoryactivityandcholinergicfunction,”Journal of Ginseng Research, vol. 35, no. 4, p. 421, 2011.

[158] S. K. Singh, S. Srivastav, R. J. Castellani, G. Plascencia-Villa, and G. Perry, “Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD andother neurological disorders,” Neurotherapeutics, vol. 16, no. 3, pp. 666–674, 2019.

[159] J. Zhao, K. Li, Y. Wang et al., “Enhanced anti-amnestic effect of donepezil by Ginkgo biloba extract (EGb 761) via further improvementinpro-cholinergicandantioxidativeactivities,” Journal of Ethnopharmacology, vol. 269, p. 113711, 2021.

[160] H. Liu, M. Ye, and H. Guo, “An updated review of randomized clinical trials testing the improvement of cognitive function of Ginkgo biloba extract in healthy people and Alzheimer’s patients,” Frontiers in Pharmacology, vol. 10, p. 1688, 2020.

[161] L. Golchin, M. Shabani, S. Harandi, and M. Razavinasab, “Pistachio supplementation attenuates motor and cognition impairments induced by cisplatin or vincristine in rats,” Advanced Biomedical Research, vol. 4, 2015.

[162] M. S. Uddin, A. Al Mamun, M. S. Hossain, F. Akter, M. A. Iqbal, and M. Asaduzzaman, “Exploring the effect of Phyllanthus emblica L. on cognitive performance, brain antioxidant markers and acetylcholinesterase activity in rats: promising natural gift for the mitigation of Alzheimer's disease,” Annals of Neurosciences, vol. 23, no. 4, pp. 218–229, 2016.

[163] R. A. El-Shiekh, R. M. Ashour, E. A. Abd El-Haleim, K. A. Ahmed,andE.Abdel-Sattar,“HibiscussabdariffaL.:apotent natural neuroprotective agent for the prevention of streptozotocin-induced Alzheimer’s disease in mice,” Biomedicine & Pharmacotherapy, vol. 128, p. 110303, 2020.

[164] J.-C. Lee, M.-F. Hou, H.-W. Huang etal., “Marine algalnatural products with anti-oxidative, anti-inflammatory, and anti-cancer properties,” Cancer Cell International, vol. 13, no. 1, pp. 1–7, 2013.

[165] E.-J. Koh, K.-J. Kim, J.-H. Song et al., “Spirulina maxima extract ameliorates learning and memory impairments via inhibitingGSK-3βphosphorylationinducedbyintracerebroventricular injection of amyloid-β 1–42 in mice,” International Journal of Molecular Sciences, vol. 18, no. 11, p. 2401, 2017.

[166] E.-J.Koh,K.-J. Kim, J.Choi, D.-H.Kang, andB.-Y. Lee, “Spirulina maxima extract prevents cell death through BDNF activation against amyloid beta 1-42 (Aβ1-42) induced neurotoxicity in PC12 cells,” Neuroscience Letters, vol. 673, pp. 33–38, 2018. [167] M. Y. Um, D. W. Lim, H. J. Son, S. Cho, and C. Lee, “Phlorotannin-rich fraction from Ishige foliacea brown seaweed

[167] M. Y. Um, D. W. Lim, H. J. Son, S. Cho, and C. Lee, “Phlorotannin-rich fraction from Ishige foliacea brown seaweed prevents the scopolamine-induced memory impairment via regulation of ERK-CREB-BDNF pathway,” Journal of Functional Foods, vol. 40, pp. 110–116, 2018.

[168] P. Pribis, R. N. Bailey, A. A. Russell et al., “Effects of walnut consumption on cognitive performance in young adults,” British Journal of Nutrition, vol. 107, no. 9, pp. 1393–1401, 2012.

[169] J. Zou, P.-s. Cai, C.-m. Xiong, and J.-l. Ruan, “Neuroprotective effect of peptides extracted from walnut (Juglans Sigilata Dode) proteins on Aβ25-35-induced memory impairment in mice,” Journal of Huazhong University of Science and Technology [Medical Sciences], vol. 36, no. 1, pp. 21–30, 2016.

[170] W. Li, T. Zhao, J. Zhang et al., “Effect of walnut protein hydrolysate on scopolamine-induced learning and memory deficits in mice,” Journal of Food Science and Technology, vol. 54, no. 10, pp. 3102–3110, 2017.

[171] A. Chauhan and V. Chauhan, “Beneficial effects of walnuts on cognition and brain health,” Nutrients, vol. 12, no. 2, p. 550, 2020.

[172] B. Muthaiyah, M. M. Essa, V. Chauhan, and A. Chauhan, “Protective effects of walnut extract against amyloid beta peptide-induced cell death and oxidative stress in PC12 cells,” Neurochemical Research, vol. 36, no. 11, pp. 2096– 2103, 2011.

[173] K. S. Kulkarni, S. Kasture, and S. Mengi, “Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats,” Indian Journal of Pharmacology, vol. 42, no. 3, p. 168, 2010.

[174] S.Haider,Z.Batool,andD.Haleem,“Nootropicandhypophagic effects following long term intake of almonds (Prunus amygdalus) in rats,” Nutricion Hospitalaria, vol. 27, no. 6, pp. 2109–2115, 2012.

[175] Z. Batool, S. Sadir, L. Liaquat et al., “Repeated administration of almonds increases brain acetylcholine levels and enhances memory function in healthy rats while attenuates memory deficitsinanimalmodelofamnesia,”BrainResearchBulletin, vol. 120, pp. 63–74, 2016.

[176] Z. Batool, F. Agha, S. Ahmad et al., “Attenuation of cadmium-induced decline in spatial, habituation and recognition memory by long-term administration of almond and walnut supplementation: role of cholinergic function,” Pak J Pharm Sci, vol. 30, no. 1, pp. 273–279, 2017.

[177] N. Gorji, R. Moeini, and Z. Memariani, “Almond, hazelnut and walnut, three nuts for neuroprotection in Alzheimer’s disease: a neuropharmacological review of their bioactive constituents,” Pharmacological Research, vol. 129, pp. 115– 127, 2018.

[178] Z. Bahaeddin, A. Yans, F. Khodagholi, H. Hajimehdipoor, and S. Sahranavard, “Hazelnut and neuroprotection: improved memory and hindered anxiety in response to intra-hippocampal Aβ injection,” Nutritional Neuroscience, vol. 20, no. 6, pp. 317–326, 2017.

[179] R. Peters, J. Peters, J. Warner, N. Beckett, and C. Bulpitt, “Alcohol,dementiaandcognitivedeclineintheelderly:asystematic review,” Age and Ageing, vol. 37, no. 5, pp. 505–512, 2008.

[180] J. A. Loureiro, S. Andrade, A. Duarte et al., “Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease,” Molecules, vol. 22, no. 2, p. 277, 2017.

[181] Z. Siahmard, H. Alaei, P. Reisi, and A. A. Pilehvarian, “The effect of red grape juice on Alzheimer's disease in rats,” Advanced Biomedical Research, vol. 1, p. 63, 2012. [182] Q. Sun, N. Jia, X. Li, J. Yang, and G. Chen, “Grape seed proanthocyanidins ameliorate neuronal oxidative damage by inhibiting GSK-3β-dependent mitochondrial permeability transition pore opening in an experimental model of sporadic Alzheimer’s disease,” Aging, vol. 11, no. 12, p. 4107, 2019.

[183] Q. Lian, Y. Nie, X. Zhang et al., “Effects of grape seed proanthocyanidin on Alzheimer's disease in vitro and in vivo,” Experimental and Therapeutic Medicine, vol. 12, no. 3, pp. 1681–1692, 2016.

[184] I. H. Borai, M. K. Ezz, M. Z. Rizk et al., “Therapeutic impact of grape leaves polyphenols on certain biochemical and neurological markers in AlCl3-induced Alzheimer’s disease,” Biomedicine & Pharmacotherapy, vol. 93, pp. 837–851, 2017.

[185] W. Pannangrong, J. Wattanathorn, S. Muchimapura, S. Tiamkao, and T. Tong-Un, “Purple rice berry is neuroprotective and enhances cognition in a rat model of Alzheimer's disease,” Journal of Medicinal Food, vol. 14, no. 7-8, pp. 688– 694, 2011.

[186] G.Oboh,A.O.Ademiluyi,andA. J.Akinyemi,“Inhibitionof acetylcholinesterase activities and some pro-oxidant induced lipidperoxidationinratbrainbytwovarietiesofginger(Zingiber officinale),” Experimental and Toxicologic Pathology, vol. 64, no. 4, pp. 315–319, 2012.

[187] B. H. Ali, G. Blunden, M. O. Tanira, and A. Nemmar, “Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research,” Food and Chemical Toxicology, vol. 46, no. 2, pp. 409–420, 2008. [188] H. Y. Huang, J. J. Huang, T. K. Tso, Y. C. Tsai, and C. K. Chang, “Antioxidant and angiotension converting enzyme inhibition capacities of various parts of Benincasa hispida (wax gourd),” Food/Nahrung, vol. 48, no. 3, pp. 230–233, 2004. [189] X. L. Li, B. Q. Zhao, Q. Li et al., “Effects of Chinese herbal medicine fuzhisan on aged rats,” Experimental Gerontology, vol. 43, no. 9, pp. 853–858, 2008.

[190] J. Zhao, D. Wang, S. Duan, J. Wang, J. Bai, and W. Li, “Analysis of Fuzhisan and quantitation of baicalin and ginsenoside Rb 1 by HPLC-DAD-ELSD,” Archives of Pharmacal Research, vol. 32, no. 7, pp. 989–996, 2009.

[191] O. Sanders and L. Rajagopal, “Phosphodiesterase inhibitors for Alzheimer’s disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale,” Journal of Alzheimer's Disease Reports, vol. 4, no. 1, pp. 185–215, 2020.

[192] P. Guo, D. Wang, X. Wang et al., “Effect and mechanism of fuzhisananddonepezil onthesirtuin1pathway andamyloid precursorproteinmetabolisminPC12cells,”MolecularMedicine Reports, vol. 13, no. 4, pp. 3539–3546, 2016.

[193] H.-S. Lim, Y. J. Kim, E. Sohn, J. Yoon, B.-Y. Kim, and S.J. Jeong, “Bojungikgi-Tang, a traditional herbal formula, exerts neuroprotective effects and ameliorates memory impairments in Alzheimer’s disease-like experimental models,” Nutrients, vol. 10, no. 12, p. 1952, 2018. [194] M. Zahoor, R. Zafar, and N. U. Rahman, “Isolation and identification of phenolic antioxidants from Pistacia integerrima gall and their anticholine esterase activities,” Heliyon, vol. 4, no. 12, p. e01007, 2018.

[195] M. S. Uddin, A. Al Mamun, M. S. Hossain et al., “Neuroprotective effect of Phyllanthus acidus L. on learning and memory impairment in scopolamine-induced animal model of dementia and oxidative stress: natural wonder for regulating the development and progression of Alzheimer’s disease,” Advances in Alzheimer's Disease, vol. 5, no. 2, pp. 53–72, 2016. [196] W.J.Hashmi,H.Ismail,F.Mehmood,andB.Mirza,“Neuroprotective, antidiabetic and antioxidant effect of Hedera nepalensis and lupeol against STZ+ AlCl 3 induced rats model,” DARU Journal of Pharmaceutical Sciences, vol. 26, no. 2, pp. 179–190, 2018. [197] B. Zhu, Z. Li, P. Y. Qian, and K. Herrup, “Marine bacterial extractsasanewrichsourceofdrugsagainstAlzheimer’sdisease,”JournalofNeurochemistry,vol.152,no.4, pp.493–508, 2020.

[198] B. R. Ahn, H. E. Moon, H. R. Kim, H. A. Jung, and J. S. Choi, “Neuroprotective effect of edible brown alga Eisenia bicyclis on amyloid beta peptide-induced toxicity in PC12 cells,” Archives of Pharmacal Research, vol. 35, no. 11, pp. 1989– 1998, 2012.

[199] M. R. Khazdair, A. Anaeigoudari, M. Hashemzehi, and R.Mohebbati,“Neuroprotectivepotencyofsomespiceherbs, a literature review,” Journal of Traditional and Complementary Medicine, vol. 9, no. 2, pp. 98–105, 2019.

[200] M. Pulido-Moran, J. Moreno-Fernandez, C. Ramirez-Tortosa, and M. Ramirez-Tortosa, “Curcumin and health,” Molecules, vol. 21, no. 3, p. 264, 2016.

[201] H. Geun Kim and M. Sook Oh, “Herbal medicines for the prevention and treatment of Alzheimer's disease,” Current Pharmaceutical Design, vol. 18, no. 1, pp. 57–75, 2012.

[202] S. Yuliani, Mustofa, and G. Partadiredja, “The neuroprotective effects of an ethanolic turmeric (Curcuma longa L.) extract against trimethyltin-induced oxidative stress in rats,” Nutritional Neuroscience, vol. 22, no. 11, pp. 797–804, 2019.

[203] Y.Kadri, R.Nciri,N.Brahmi etal., “ProtectiveeffectsofCurcuma longa against neurobehavioral and neurochemical damage caused by cerium chloride in mice,” Environmental Science and Pollution Research, vol. 25, no. 20, pp. 19555– 19565, 2018.

[204] N. Hishikawa, Y. Takahashi, Y. Amakusa et al., “Effects of turmeric on Alzheimer's disease with behavioral and psychological symptoms of dementia,” Ayu, vol. 33, no. 4, pp. 499– 504, 2012.

[205] T.-P. Ng, P.-C. Chiam, T. Lee, H.-C. Chua, L. Lim, and E.H. Kua, “Curry consumption and cognitive function in the elderly,” American Journal of Epidemiology, vol. 164, no. 9, pp. 898–906, 2006.

[206] B. Mathew and R. Biju, “Neuroprotective effects of garlic a review,” Libyan Journal of Medicine, vol. 3, no. 1, pp. 23–33, 2006.

[207] B. Sripanidkulchai, “Benefits of aged garlic extract on Alzheimer's disease: possible mechanisms of action,” Experimental and Therapeutic Medicine, vol. 19, no. 2, pp. 1560–1564, 2020. [208] N. Nillert, W. Pannangrong, J. U. Welbat, W. Chaijaroonkhanarak, K. Sripanidkulchai,

and B. Sripanidkulchai, “Neuroprotective effects of aged garlic extract on cognitive dysfunction and neuroinflammation induced by β-amyloid in rats,” N

[209] K.-A. Hwang, Y.-J. Hwang, I.-G. Hwang, J. Song, and Y. J. Kim, “Low temperature-aged garlic extract suppresses psychological stress by modulation of stress hormones and oxidative stress response in brain,” Journal of the Chinese Medical Association, vol. 82, no. 3, pp. 191–195, 2019.

[210] H.-J. Huang, S.-L. Chen, Y.-T. Chang, J.-H. Chyuan, and H. M. Hsieh-Li, “Administration of Momordica charantia enhances the neuroprotection and reduces the side effects of LiCl in the treatment of Alzheimer’s disease,” Nutrients, vol. 10, no. 12, p. 1888, 2018.

[211] A. Russo and F. Borrelli, “Bacopa monniera, a reputed nootropic plant: an overview,” Phytomedicine, vol. 12, no. 4, pp. 305–317, 2005.

[212] M. Dhanasekaran, B. Tharakan, L. A. Holcomb, A. R. Hitt, K. A. Young, and B. V. Manyam, “Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monniera,” Phytotherapy Research, vol. 21, no. 10, pp. 965–969, 2007.

[213] N. Uabundit, J. Wattanathorn, S. Mucimapura, and K.Ingkaninan,“Cognitiveenhancementandneuroprotective effects of Bacopa monnieri in Alzheimer's disease model,” Journal of Ethnopharmacology, vol. 127, no. 1, pp. 26–31, 2010.

[214] S. Bhattacharya, A. Bhattacharya, A. Kumar, and S. Ghosal, “Antioxidant activity ofBacopa monniera in rat frontal cortex, striatum and hippocampus,” Phytotherapy Research, vol. 14, no. 3, pp. 174–179, 2000.

[215] N. Limpeanchob, S. Jaipan, S. Rattanakaruna, W. Phrompittayarat, and K. Ingkaninan, “Neuroprotective effect of _Bacopa monnieri_ on beta-amyloid-induced cell death in primary cortical culture,” Journal of Ethnopharmacology, vol. 120, no. 1, pp. 112–117, 2008.

[216] A. Sadhu, P. Upadhyay, A. Agrawal et al., “Management of cognitive determinants in senile dementia of Alzheimer’s type: therapeutic potential of a novel polyherbal drug product,” Clinical Drug Investigation, vol. 34, no. 12, pp. 857– 869, 2014.

[217] A. Szurpnicka, A. Kowalczuk, and A. Szterk, “Biological activity of mistletoe: in vitro and in vivo studies and mechanisms of action,” Archives of Pharmacal Research, vol. 43, no. 6, pp. 1–37, 2008.

[218] R. Moeini, Z. Memariani, F. Asadi, M. Bozorgi, and N. Gorji, “Pistacia genus as a potential source of neuroprotective natural products,” Planta Medica, vol. 85, no. 17, pp. 1326–1350, 2019.

[219] Q. F. Liu, Y. Jeon, Y.-w. Sung et al., “Nardostachys jatamansi ethanol extract ameliorates Aβ42 cytotoxicity,” Biological and Pharmaceutical Bulletin, vol. 41, no. 4, pp. 470–477, 2018.

[220] Q.F.Liu,J.H.Lee,Y.-M.Kimetal.,“Invivoscreeningoftraditional medicinal plants for neuroprotective activity against Aβ42cytotoxicitybyusingDrosophilamodelsofAlzheimer’s disease,” Biological and Pharmaceutical Bulletin, vol. 38, pp. b15–00459, 2015.

[221] A. Alagan, I. Jantan, E. Kumolosasi, S. Ogawa, M. A. Abdullah, and N. Azmi, “Protective effects of Phyllanthus amarus against lipopolysaccharide-induced neuroinflammation and cognitive impairment in rats,” Frontiers in Pharmacology, vol. 10, p. 632, 2019.

[222] H.Yu, L.Yao, H.Zhou etal., “Neuroprotectionagainst Aβ2535-induced apoptosis by Salvia miltiorrhiza extract in SH

20 Oxidative Medicine and Cellular Longevity

SY5Ycells,”NeurochemistryInternational,vol.75,pp.89–95, 2014.

[223] W.-Y.Jiang,B.-H.Jeon,Y.-C.Kim,S.H.Lee,D.H.Sohn,and G.S.Seo,“PF2401-SF,standardizedfractionofSalviamiltiorrhiza shows anti-inflammatory activity in macrophages and acute arthritis in vivo,” International Immunopharmacology, vol. 16, no. 2, pp. 160–164, 2013.

[224] L.Hu,J. Yu,F.Li,B.Chen,L.Li,andG.Liu, “EffectsofSalvia miltorrhizainneuraldifferentiationofratmesenchymalstem cells with optimized protocol,” Journal of Ethnopharmacology, vol. 136, no. 2, pp. 334–340, 2011.

[225] T. Shu, M. Pang, L. Rong et al., “Effects of Salvia miltiorrhiza on neural differentiation of induced pluripotent stem cells,” Journal of Ethnopharmacology, vol. 153, no. 1, pp. 233–241, 2014.

[226] N. J. Dar and G. W. Glazner, “Deciphering the neuroprotective and neurogenic potential of soluble amyloid precursor protein alpha (sAPPα),” Cellular and Molecular Life Sciences, vol. 77, no. 12, pp. 2315–2330, 2020.

[227] P. He, P. Schulz, and M. R. Sierks, “A conformation-specific antibody against oligomeric β-amyloid restores neuronal integrity in a mouse model of Alzheimer's disease,” Journal of Biological Chemistry, vol. 296, p. 100241, 2021.

[228]M.T.Kabir,M.Uddin,B.Mathew,P.K.Das,A.Perveen,and G.M.Ashraf,“EmergingpromiseofimmunotherapyforAlzheimer’s disease: a new hope for the development of Alzheimer’s vaccine,” Current Topics in Medicinal Chemistry, vol. 20, no. 13, pp. 1214–1234, 2020.

[229] R. E. Lackie, J. Marques-Lopes, V. G. Ostapchenko et al., “Increased levels of Stress-inducible phosphoprotein-1 acceleratesamyloid-βdepositioninamousemodelofAlzheimer’s disease,” Acta Neuropathologica Communications, vol. 8, no. 1, pp. 119–143, 2020.

[230] K. Lobello, J. M. Ryan, E. Liu, G. Rippon, and R. Black, “Targeting beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease,” International Journal of Alzheimer’s Disease, vol. 2012, 14 pages, 2012.

[231] R. Vassar and P. C. Kandalepas, “The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease,” Alzheimer's Research & Therapy, vol. 3, no. 3, pp. 1–6, 2011.

[232] Y. Li, W. Zhou, Y. Tong, G. He, and W. Song, “Control of APP processing and Aβ generation level by BACE1 enzymatic activity and transcription,” The FASEB Journal, vol. 20, no. 2, pp. 285–292, 2006.

[233] C. Zhang, “Natural compounds that modulate BACE1processing of amyloid-beta precursor protein in Alzheimer’s disease,” Discovery Medicine, vol. 14, no. 76, pp. 189–197, 2012.

[234] B. De Strooper, T. Iwatsubo, and M. S. Wolfe, “Presenilins andSecretase:Structure,Function,androleinAlzheimerdisease,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 1, p. a006304, 1998.

[235] A. Escamilla-Ayala, R. Wouters, R. Sannerud, and W. Annaert, “Contribution of the presenilins in the cell biology, structure and function of γ-secretase,” In Seminars in Cell & Developmental Biology, vol. 105, pp. 12–26, 2020.

[236] A.F.Kreft,R.Martone,andA.Porte,“Recentadvancesinthe identificationofγ-secretaseinhibitorstoclinicallytesttheAβ oligomer hypothesis of Alzheimer’s disease,” Journal of Medicinal Chemistry, vol. 52, no. 20, pp. 6169–6188, 2009.

[237] S.C.Mayer,A.F.Kreft,B.Harrisonetal.,“Discoveryofbegacestat, a Notch-1-sparing γ-secretase inhibitor for the treatment of Alzheimer’s disease,” Journal of Medicinal Chemistry, vol. 51, no. 23, pp. 7348–7351, 2020.

[238] D. Hanger, B. Anderton, and W. Noble, “Phosphorylation: the therapeutic challenge for neurodegenerative disease,” Trends Mol. Med, vol. 15, pp. 112–119, 2009.

[239] M. Kolarova, F. García-Sierra, A. Bartos, J. Ricny, and D. Ripova,“Structure andpathologyof tau proteinin Alzheimer disease,” International Journal of Alzheimer’s Disease, vol. 2012, 13 pages, 2012.

[240] K. Santacruz, J. Lewis, T. Spires et al., “Tau suppression in a neurodegenerative mouse model improves memory function,” Science, vol. 309, no. 5733, pp. 476–481, 2005.

[241] C. Andorfer, C. M. Acker, Y. Kress, P. R. Hof, K. Duff, and P. Davies, “Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms,” Journal of Neuroscience, vol. 25, no. 22, pp. 5446–5454, 2005.

[242] F. Hernández, E. G. de Barreda, A. Fuster-Matanzo, J. J. Lucas, and J. Avila, “GSK3: a possiblelink between beta amyloid peptide and tau protein,” Experimental Neurology, vol. 223, no. 2, pp. 322–325, 2010.

[243] H.-K. Lee, P. Kumar, Q. Fu, K. M. Rosen, and H. W. Querfurth, “The insulin/Akt signaling pathway is targeted by intracellular β-amyloid,” Molecular Biology of the Cell, vol. 20, no. 5, pp. 1533–1544, 2009.

[244] B. Georgievska, J. Sandin, J. Doherty et al., “AZD 1080, a novel GSK 3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans,” Journal of Neurochemistry, vol. 125, no. 3, pp. 446–456, 2013.

[245] K. Sugaya, E. Giacobini, and V. Chiappinelli, “Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease,” Journal of Neuroscience Research, vol. 27, no. 3, pp. 349–359, 1990.

[246] T. Kihara, S. Shimohama, M. Urushitani et al., “Stimulation of α 4 β 2 nicotinic acetylcholine receptors inhibits β -amyloid toxicity,” Brain Research, vol. 792, no. 2, pp. 331–334, 1998.

[247] S. D. Buckingham, A. K. Jones, L. A. Brown, and D. B. Sattelle, “Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection,” Pharmacological Reviews, vol. 61, no. 1, pp. 39–61, 2009.

[248] E. Alonso, C. Vale, M. R. Vieytes, F. M. Laferla, L. GiménezLlort, and L. M. Botana, “The cholinergic antagonist gymnodimine improves Aβ and tau neuropathology in an in vitro model of Alzheimer disease,” Cellular Physiology and Biochemistry, vol. 27, no. 6, pp. 783–794, 2011.

[249] M. Mehta, A. Adem, and M. Sabbagh, “New acetylcholinesterase inhibitors for Alzheimer's disease,” International Journal of Alzheimer’s Disease, vol. 2012, 8 pages, 2012.

[250] J. J. Sramek, E. J. Frackiewicz, and N. R. Cutler, “Review of the acetylcholinesterase inhibitor galanthamine,” Expert Opinion on Investigational Drugs, vol. 9, no. 10, pp. 2393–2402, 2000.

[251] S. Akhondzadeh, M. Noroozian, M. Mohammadi, S. Ohadinia, A. Jamshidi, and M. Khani, “Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 74, no. 7, pp. 863–866, 2003.

21Oxidative Medicine and Cellular Longevity

[252] S. Akhondzadeh and M. Noroozian, “Alzheimer's disease: pathophysiologyandpharmacotherapy,”IDrugs:TheInvestigational Drugs Journal, vol. 5, no. 11, pp. 1062–1069, 2002.

[253] V. C. Mok, S. Pendlebury, A. Wong et al., “Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future,” Alzheimer's & Dementia, vol. 16, no. 11, pp. 1571–1581, 2020.

[254] H. Ning,R. Li, X.Ye,Y. Zhang,andL. Liu, “Areview on serious games for dementia care in ageing societies,” IEEE Journal of Translational Engineering in Health and Medicine, utrients, vol. 9, no. 1, p. 24, 2017.